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Abstract 
 
 Changes in hygiene and dietary habits, including increased consumption 
of foods high in fat, simple sugars, and salt that are known to impact the 
composition and function of the intestinal microbiota, may explain the increase 
in prevalence of chronic inflammatory diseases. High salt consumption has been 
shown to worsen autoimmune encephalomyelitis and colitis in mouse models 
through p38/MAPK signaling pathway. However, the effect of high salt diet 
(HSD) on gut microbiota and on intestinal immune homeostasis, and their roles 
in determining vulnerability to intestinal inflammatory stimuli are unknown. 
Here, we investigate the role of gut microbiota alterations induced by HSD on 
the severity of murine experimental colitis. 
Compared to control diet, HSD altered fecal microbiota composition and 
function, reducing Lactobacillus sp. relative abundance and butyrate production. 
Moreover, HSD affected the colonic, and to a lesser extent small intestinal 
mucosal immunity by enhancing the expression of pro-inflammatory genes such 
as Rac1, Map2k1, Map2k6, Atf2, while suppressing many cytokine and 
chemokine genes, such as Ccl3, Ccl4, Cxcl2, Cxcr4, Ccr7. Conventionally raised 
mice fed with HSD developed more severe DSS- (dextran sodium sulfate) and 
DNBS- (dinitrobenzene sulfonic acid) induced colitis compared to mice on 
control diet, and this effect was absent in germ-free mice. Transfer experiments 
into germ-free mice indicated that the HSD-associated microbiota profile is 
critically dependent on continued exposure to dietary salt. 
Our results indicate that the exacerbation of colitis induced by HSD is 
associated with reduction in Lactobacillus sp. and protective short-chain fatty 
acid production, as well as changes in host immune status. We hypothesize that 
these changes alter gut immune homeostasis and lead to increased vulnerability 
to inflammatory insults. This study provides an example of how the gut 
microbiota plays an essential intermediary role between environmental factors, 
such as diet, and host physiology. Furthermore, this thesis indicates the high 
salt consumption as a potential risk factor for inflammatory bowel diseases. 
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Resumo 
 
 
Mudanças nos hábitos higiénicos e alimentares, incluindo o consumo de 
alimentação com alto teor de gordura, açucares simples e sal - que se sabe 
exercerem um impacto na composição e função da microbiota intestinal – 
podem explicar o aumento da prevalência de doenças imunes crónicas. Foi 
recentemente demonstrado que o consumo de alto teor de sal tem um efeito 
adverso no desenvolvimento de encefalomielite autoimune e colite em ratinhos 
através da cascata de sinalização p38/MAPK. No entanto, ainda é desconhecido 
o efeito da dieta com alto teor de sal (DS) na estrutura da microbiota intestinal 
(ou flora intestinal) e na homeostasia do sistema imune; bem como o seu papel 
na vulnerabilidade para responder a estímulos imunológicos no intestine. Neste 
estudo, investigámos o papel que as alterações na microbiota intestinal 
induzidas por DS, exerce na severidade do desenvolvimento de colite em 
ratinhos. 
Comparado com a dieta controlo, a DS induz a alteração da composição e 
função  da microbiota fecal, nomeadamente a redução da abundancia relativa 
de Lactobacillus sp. e produção de butirato. Além disso, DS afectou a imunidade 
da mucosa intestinal no cólon e, de uma maneira menos proeminente, do 
intestino delgado. DS induziu a expressão de genes pro-inflamatórios como por 
exemplo Rac1, Map2k1, Map2k6, Atf2, e suprimiu genes de várias citocinas e 
quimiocinas, dos quais Ccl3, Ccl4, Cxcl2, Cxcr4, Ccr7. Ratinhos alimentados 
com DS desenvolveram uma colite mais severa usando os modelos de colite 
induzida por DSS e DNBS, quando comparados com ratinhos em dieta controle. 
Este efeito esteve ausente quando usados ratinhos desprovidos de bactérias 
(Germ Free mice). Experiências de transferência de microbiota para ratinhos 
desprovidos de bactérias indicaram que a microbiota associada a DS precisa 
duma exposição continuada a DS para manter o seu perfil. 
Os nossos resultados indicam que o agravamento da colite induzido pela 
DS está associada à redução de Lactobacillus sp e à produção de butirato, bem 
como a mudanças no status imunológico do hospedeiro. Nós propomos que 
estas mudanças alteram a homeostasia da imunidade nos intestinos, o que leva 
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ao aumento da vulnerabilidade aos insultos inflamatórios. Este estudo 
apresenta-se como um exemplo do papel essencial que a macrobiota intestinal 
desempenha na intermediação entre factores ambientais, como a dieta, e a 
fisiologia do hospedeiro. Além disso, esta tese indica o consumo elevado de sal 
como um potencial factor de risco em doenças intestinais inflamatórias. 
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I – General Introduction 
 
 
1. Chronic inflammatory disorders: incidence in the 
“Western world” 
 
 The incidence of chronic diseases, namely related to some form of 
immune disorder, such as inflammatory bowel disease (IBD), multiple sclerosis 
(MS), diabetes, asthma, rheumatoid arthritis (RA), and others has been 
increasing over the past 50 years, namely in the “Western” (industrialized) 
regions of the planet [1,2]. Although many of these chronic immune disorders 
(CID) have been linked to genetic susceptibility factors, genetic drift alone can 
not explain the population incidence rising of CID over the last half-century [3]. 
Moreover, a relatively low concordance rate for most of autoimmune diseases 
between monozygotic twins suggests non-genetic factors as important triggers 
of disease [4]. Several of these non-genetic factors have been proposed to 
explain the rise of chronic immune related disorders, including decreased 
incidence of in infectious diseases (the so called “hygiene hypothesis”) [1,5] (Fig. 
1), as well as environmental factors related to changes in life-style observed in 
the western world, in particular dietary and hygiene factors [6].  
 
 
 
 
 
 
 
 
 
Figure 1. Hygiene hypothesis. Inverse relationship between the incidence of prototypical 
infectious diseases (Panel A) and the incidence of chronic immune disorders (Panel B) from 1950 
to 2000. (Figure from Bach JF, 2002[1]). 
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2. “Western diet” 
 
 
2.1. General features and implications in chronic inflammatory 
disorders 
 
 Diet have undergone significant changes over the last few decades, that 
have been considered too quick on an evolutionary time scale, for the human 
genome to adjust [7]. The Western Diet (WD) is generally characterized by high 
content of saturated fats, red meats, refined sugars and salt, while low in fresh 
fruits and vegetables with consequent low fiber content [7,8]. There is growing 
evidence from human and animal studies implicating WD factors in the 
development of CID. Epidemiological studies revealed a strong correlation of 
dietary factors such as low fiber [9] and high fat [10] consumption with CID, in 
particular IBD, diabetes and asthma [8]. However, careful approach must be 
taken when interpreting diet-disease epidemiological studies because of the 
multifactorial etiology of chronic diseases, and the complexity and often 
subjective nature of self-reported dietary patterns [11]. Interventional studies 
have uncovered a link between high fat and low fruit and vegetables 
consumption and worse asthma outcomes [12,13]. Although population studies 
have demonstrated a correlation between diet and CID, the mechanisms 
involved in diet-mediated inflammatory processes are largely unknown. Feeding 
mice with high fat diet (HFD) was shown to spontaneously increase the 
circulating proinflammatory cytokines TNFα, IL-1β and IL-6 in the plasma, and to 
induce macrophage infiltration and inflammation in the adipose tissue, in a 
TLR4 signaling pathway dependent way [14]. Moreover, it was shown in rodent 
models that a high-fat diet exacerbates models of IBD [15], experimental 
autoimmune encephalomyelitis (EAE, a rodent model mimicking aspects of MS) 
[16] and collagen-induced arthritis (CIA) [17]. 
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2.2 Salt: a new player in chronic inflammatory disorders 
  
 One dietary feature of WD that has been overlooked for its potential role 
in contributing for CID is its high salt (sodium chloride, NaCl) content. The 
consumptions of salt has increased in the Western world societies, mainly driven 
by the increased intake of processed foods and “fast food” in the industrialized 
societies, which can contain more than 100 times the salt found in similar home 
made meals [7,18,19]. In addition to well-documented effects of excess salt 
intake in increased blood pressure, cardiovascular disease and stroke [20], salt 
was recently shown to modulate aspects of the immune system and was linked 
to EAE severity in mice [21,22]. Increased NaCl concentration was able to induce 
the differentiation of a pathogenic form of Th-17 T cells from human and rodent 
naïve CD4+ T cells in vitro. This process was dependent on the activation of p38 
mitogen-activated protein kinase (P38/MAPK), nuclear factor of activated T-cells 
5 (NFAT5) and serum/glucocorticoid-regulated kinase 1 (SGK1) [21,22]. Th17 
cells are a group of CD4+RORγt+ T cells that secrete interleukin-17 (IL-17A and IL-
17F) and IL-22, and play an important role in protecting against bacterial and 
fungal pathogenic infections, particularly at mucosal surfaces [23]. Pathogenic 
IL-23-dependent Th-17 cells have been shown to be critical for the development 
of EAE in rodents and autoimmune diseases [24]. Indeed, mice receiving a salt-
enriched diet (high salt diet, HSD) developed an exacerbated form of EAE, thus 
showing for the first time a link between salt consumption and a CID in an 
animal model [21,22]. Moreover, an observational clinical study using 
regression analysis, found a positive correlation between sodium intake and 
increased disease activity in a cohort of relapsing-remitting patients with MS 
followed for two years [25]. Interestingly, in a longitudinal experiment 
performed under highly controlled spaceflight simulation program, human 
subjects were exposed to fixed salt intake changes and their immune system 
was assessed. Subjects, when exposed to HSD, displayed increased numbers of 
circulating monocytes and pro-inflammatory cytokines IL-6 and IL-23, along with 
decrease of anti-inflammatory cytokine IL-10 [26]. 
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 A possible mechanism by which dietary factors modulate physiological 
processes and in particular the immune system, is through interaction with gut 
microbiota. In fact, it is well established that diet determines the composition 
and function of the gut microbiota, with repercussions for health and disease 
[27]. 
 
 
3. Gut Microbiota 
 
3.1. Overview 
 
 Accumulating data suggest that gut microbiota plays an essential role in 
host health and disease. It consists of a living consortium of different 
microorganisms such as Bacteria and Archaea, Eukarya and Viruses inhabiting 
the gastro-intestinal tract (GI tract), that have co-evolved with the host over 
thousands of years into a complex symbiotic mutualistic relationship. While the 
host provides a protected habitat and the necessary substrate, the gut 
microbiota contributes by controlling a vast enzymatic repertoire, essential for 
gut physiology, metabolic, immune and neuronal functions. 	
 Bacteria numbers in the human body were estimated to account for ≈ 
1014, thus exceeding human body cells by 10:1. These numbers were however 
recently revisited, after the original estimation was traced back to an old “back-
of-the-envelope calculations” published in the 1970’s [28,29]. In the new 
proposed estimation, the number of total bacteria was estimated to ≈ 3.813, 
resulting in a ≈ 1:1 ratio of bacteria to human cells [29,30]. Even more relevant, 
the largest human gut microbiome (the sum of all genes in the microbiota) 
metagenomics analysis to date [31], has identified around 10 million non-
redundant genes from a multi-continental human consortium including 
Europeans, Chinese and American subjects, comprising of an average of ≈ 
750,000 genes per sample. These numbers completely dwarf the 19,000-20,000 
protein-coding genes that comprise the human genome [32], indicating that the 
gut microbiome gene pool is 500x larger than human genome, and that an 
General Introduction 
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average human gut microbiome contains 40x more genes than the human host 
genome itself.  
 Microbiota populates the entire GI tract, from mouth to rectum, but the 
density and composition of bacteria varies greatly along the gut. While the 
upper GI tract contains low density of predominantly aerobic bacteria, the lower 
GI tract harbors higher density numbers of anaerobic and facultative anaerobic 
bacteria, ranging from 103-104 bacteria/ml in the stomach and duodenum, to 
1011 bacteria/ml in the colon, which harbors the vast majority of the body’s 
bacterial load [33]. This heterogeneous pattern is a reflection of several 
determinant factors such as pH and oxygen level, as well as the content flow 
speed through the tract. Low pH and faster content flow, typical of the stomach 
and the upper part of small intestine impose a harsh environment that limits 
bacteria colonization, and vice-versa. This diversity makes the GI tract a 
continuous collection of different micro ecosystems, with specialized functions 
and microbiota-host interactions. 
 The development of culture-independent technologies based on the 
sequencing of gut microbiota genetic information, started a new era in our 
understanding of the role of microbiota in host’s health and disease, by 
allowing a deeper monitoring and quantification of microbiota composition, 
function and dynamics, in a relatively fast and low cost manner. Perturbations in 
gut microbiota composition and function, known as dysbiosis, have been 
extensively associated to multiple diseases, ranging from intestinal disorders to 
metabolic, hepatic, neuronal, respiratory and immune-related diseases. In fact, 
gut microbiota has gained tremendous attention as a potential key mediator 
between the rapid changes occurring in environmental factors and life-style and 
the rise of the incidence of several diseases, as this cannot be explained by the 
human population genetic drift alone. 
 
 This thesis will be focus on the bacteria that inhabits the GI tract. So for 
simplicity purposes, I will be referring to bacteria when mentioning microbiota. 
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3.2. Development of the human gut microbiota 
 
 Historically, the newborn infant was considered to be sterile until the 
mother has given the initial microbiota inoculum at birth, from the vaginal or 
skin microbiota, at natural birth or C-section respectively. However, this dogma 
was challenged by DNA-based studies that shown undeniable evidence of the 
microbial presence in the healthy placenta, amniotic fluid [34,35], umbilical cord 
[36] and meconium [37,38] (the first stool of a newborn). It is still unclear how 
bacteria penetrate the intrauterine environment but in one experiment, specific 
labeled bacteria fed to pregnant mice has been detected in the meconium of the 
offspring, suggesting that intrauterine bacteria can be transmitted from the 
mother’s GI tract [37].  
 After birth, the GI tract becomes rapidly colonized, with the neonatal gut 
microbiota composition being determined by several factors such as the mode 
of delivery (vaginal or C-section), gestational age, diet (breast milk or milk 
formula) and early antibiotic treatment [39–42]. Early assembly of gut 
microbiota is a non-random process with different species appearing at different 
time points, beginning with the establishment of oxygen tolerant bacterial 
species mainly from Firmicutes and Proteobacteria phylum, which reduce the GI 
tract environment allowing the further establishment of strict anaerobic species 
such as Bifidobacterium and Bacteroides [40,41,43]. Over time, the microbiota 
diversity rapidly increases until an adult-like microbiota community dominated 
by the bacteria phylum Bacteroidetes and Firmicutes becomes established at 
around 2-4 years old [40,41,43]. In the elderly, the gut microbiota suffers a 
general loss of diversity, a reduction of beneficial bacteria such as 
Bifidobacterium spp and changes in metabolic pathways such as the decrease of 
Short Chain Fatty Acid (SCFA) production, a class of bacteria metabolites 
essential for intestinal function, that will be discussed bellow [44–46].  
 Several studies have attempted to define healthy gut microbiota 
enterotypes (defined types of microbial communities) [47,48] based on diet 
habits or geographical distribution of the population. However, and despite the 
efforts this concept remains controversial due to the disparities found across 
multiple studies and the sensitivity of the clustering methods applied in 
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defining microbiota enterotypes [49,50]. In the past decade, two major 
population-scale studies, The Human Microbiome Project (HMP, [51,52]) and the 
Metagenomics of the Human Intestinal Tract (MetaHIT, [31]), helped shedding 
light on the structure and diversity of healthy human microbiota. These large 
population studies confirmed that the human gut microbiota is clearly 
dominated by two bacteria phyla, Bacteroidetes and Firmicutes; accompanied by 
bacteria from Proteobacteria, Actinobacteria, Fusobacteria, Verrucomicrobia 
phyla and others. Overall, mice share the same gut core microbiota as humans, 
with a strong dominance of Bacteroidetes and Firmicutes phyla, although the 
proportions of some phyla and genera can be distinct [53,54].  
 
 
3.3 The gut microbiota functions in health 
 
 The beneficial properties that the gut microbiota provides to the host are 
diverse and include breaking down diet-derived molecules and generating new 
essential metabolites with beneficial functions to the host, contributing to 
intestinal barrier function, development and maturation of the host’s immune 
system, protecting against pathogens and even playing a role in the central 
nervous system function.  
 Studies using animals deprived of any microbes (germ-free) and studies 
using antibiotics to induce dysbiotic gut microbiota, provide an important proof-
of-principal to understand the functions and benefits of the microbiota. GF 
animals are reared in sterile isolators in order to control for the exposure of any 
microorganism. These animals can be studied in their sterile condition (germ-
free animals) or be colonized with a defined microbiota mixture (gnotobiotic 
animals). When compared to conventional mice harboring normal microbiota, GF 
mice suffer from a generalized metabolic inefficiency, as demonstrated by the 
need to consume more food to maintain the same body weight [55] or the 
resistance of these mice to diet-induced obesity [56]. GF mice are also deficient 
in some vitamins and completely lack secondary bile acids [57,58]. Moreover, 
GF mice have an immature IS, with extensive deficits in the development of the 
gut-associated lymphoid tissues (GALT), and in the production of antibodies, 
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defensins and other anti-microbial proteins. GF mice contain abnormal immune 
cell levels and have deficiencies in immune responses [59]. Defects in the gut 
barrier were also observed of GF mice, including thinner mucus layer, lower 
expression of proteins important for gut epithelial integrity and a general 
increased permeability [59]. Finally, GF mice were shown to have altered 
responses to stress, behavioral baseline and brain chemistry when compared to 
conventional mice [60].  
 Similarly to studies in GF animals, the action of antibiotics in disrupting 
the gut microbiota has helped shedding light on the beneficial role of gut 
microbiota. Most notably, antibiotics have been shown to be associated with 
intestinal pathogenic infections such as Clostridium difficile, reinforcing the 
function of commensal microbiota in the protection against pathogens [61]. 
Likewise, the use of antibiotics during development is associated with 
detrimental health consequences such as increased risk of infections, asthma, 
allergies, diabetes and obesity [62], supporting the role of gut microbiota in the 
development of the IS and metabolic function of the host. 
 
 
3.3.1. Microbiota role in host metabolism 
 
 The gut microbiota controls a vast enzymatic repertoire that exceeds by a 
large scale the host enzymatic capacity. This bacterial enzymatic machinery play 
an essential role complementing the digestion of the host’s diet, as well as by 
providing the host with a vast diversity of metabolites that are important for 
host’s health function. The large quantities of complex carbohydrates (fiber) 
that escape digestion and absorption by the small intestine are assimilated by 
colonic bacteria and fermented into different SCFA, representing the major flow 
of carbon from the diet, through the microbiome to the host [63]. SCFA are fatty 
acids with two to six carbon atoms that are small enough to be absorbed by the 
epithelial cells in the GI tract, and play an important function in host physiology 
as sources of energy and signaling molecules that act as regulators of cellular 
processes such as gene expression, chemotaxis, differentiation, proliferation 
and apoptosis [64]. The three major SCFA are acetate, propionate and butyrate 
General Introduction 
	 16 
and they differ in their potential function in host physiology. While most 
anaerobic bacteria can produce acetate, which invariably achieves the highest 
concentrations among the SCFA, propionate and butyrate are produced by 
specific groups of gut bacteria that use distinct metabolic pathways [64]. 
Propionate is produced by members of Bacteroidetes phylum, such as certain 
Bacteroides and Prevotella bacteria, whereas butyrate is mostly produced by 
members of Firmicutes phylum, mainly by bacteria of Lachnospiraceae and 
Ruminococcaceae families, but also by Actinobacteria species [64]. Butyrate has 
received much attention for its many roles in health and disease and potential 
therapeutic value [65]. Butyrate serves as the preferred metabolic substrate of 
colonic epithelial cells (colonocytes), where it is oxidized to CO
2
 in the presence 
of circulatory O
2
, resulting in the formation of ATP [66]. Butyrate has been 
shown to have anti-inflammatory properties, mainly via the inhibition of nuclear 
factor kB (NF-kB) in colonocytes [67]; and anti-cancer activity via the ability to 
induce apoptosis in colonic cancer cells [65]. Butyrate has also been shown to 
contribute to intestinal barrier integrity and to regulate the intestinal pH [68]. A 
decrease in butyrate-producing bacteria has been found in IBD patients [69] and 
is associated with expansion of pathogenic bacteria such as Salmonella [70], 
supporting the view that butyrate plays a critical role in disease resistance. 
 Vitamins are another class of beneficial metabolites that can be 
synthesized by gut microbiota. These include vitamin K and several B group 
vitamins such as biotin (B8), cobalamin (B12), folate (B9), pyridoxine (B6), 
riboflavin (B2) and others [57]. In fact, a study analyzing the biosynthesis 
pathways of eight different B-vitamins in the human gut microbiome, estimated 
that the gut microbiota contributed with over a quarter of the suggested dietary 
intake of four B vitamins [71]. Colonic bacteria can also metabolize bile acids 
that escape the enterohepatic circulation, into secondary bile acids. These 
metabolites play an important role in dietary digestion and as a microbial 
community selective pressure due to its anti-microbial properties [72]. 
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3.3.2. Microbiota role in host immune system 
 
 The co-evolution of the immune system and the gut microbiota created a 
symbiotic relationship, where the immune system maintains a tolerant stand 
towards the microbial communities inhabiting the intestine while providing 
microbial population control that ultimately benefits the community. In turn, the 
microbiota promotes and calibrates multiple aspects of the immune system 
[73]. The communication between the gut microbiota and the immune system is 
mainly mediated by the recognition of conserved microbial-associated molecular 
patterns (MAMPs) such as lipopolysaccharide (LPS) and peptidoglycans, by the 
host cells. These molecular effectors can be recognized by pattern recognition 
receptors (PRRs) in epithelial and immune cells, such as toll-like receptors (TLRs) 
and Nod-like receptors (NLR). 
 Studies in GF mice have revealed that these mice have fewer and smaller 
Peyer’s patches (PP) and mesenteric lymph nodes (MLNs), reduced numbers of 
CD4+ T cells, IgA-producing plasma cells and reduced expression of 
antimicrobial molecules and TLRs; thus illustrating the key role that microbiota 
plays in the development of host’s immune system [59]. The role of microbiota 
in the immune system starts at birth, when the first members of the microbial 
community start to colonize the GI tract and interact with the naïve IS. This early 
interaction is vital to promote the healthy colonization of the microbial 
community and benign relationship between microbiota and the immune 
system, while tuning a healthy responsive mucosal and systemic immune 
system for the long-term. In fact, early antibiotic interventions are associated 
with increased risk for diseases related to hyperreactivity of the IS such as 
asthma, allergies, Crohn’s disease, Type 1 and Type 2 Diabetes [62,74]. 
 One of the first described direct effects of a specific commensal bacteria 
on the host immune system was the role of polysaccharide A (PSA) produced by 
the commensal Bacteroides fragilis in stimulating the expansion of CD4+ T cells 
and development of lymphocyte follicles in the spleen [75].  Observations in GF 
mice and antibiotic studies have shown that the differentiation and expansion of 
Th17 populations is highly dependent on the gut microbiota [76]. Indeed, 
Ivanov et al observed that mice from a specific animal commercial vendor 
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facilities presented abnormally low numbers of Th17 cells, which could not be 
attributed to genetic differences but instead to the gut microbial composition 
[76]. Moreover, the authors showed that a particular bacteria, the segmented 
filamentous bacteria (SFB), induced differentiation and expansion of Th17 cells 
in intestinal lamina propria [77].  
 
 
3.3.3. Microbiota role in promoting epithelial barrier 
 
 An example of the mutualistic dialogue between the gut microbiota and 
the immune system is the team effort to limit bacteria contact with the epithelial 
cell surface. This is an essential strategy for maintaining the homeostasis 
between the two parts, and is accomplished by the combination of several 
factors including the epithelial cell monolayer, production of mucus, IgA, 
antimicrobial peptides and immune cells, a phenomenon that has been referred 
as the “mucosal firewall” [78]. Microbiota derived molecules such as LPS and 
SCFA stimulate different types of host cells to produce this panoply of immune 
factors that will limit microbial translocation to lamina propria and tissue 
inflammation, which could result in damaging consequences for both the 
microbial community and the host health [79]. Deficiencies in this balance are 
suggested to play a role in the development of IBD. Indeed, patients with IBD 
have increased numbers of epithelial cell surface-associated bacteria [80] and 
patients with PRR NOD2 defects, one of the first identified IBD risk allele, have 
lower antimicrobial α-defensin production [81]. 
 Several bacteria species have been linked to promoting epithelial 
integrity. Akkermansia muciniphila and Lactobacillus plantarum were shown to 
upregulate tight junction proteins and reduce gut permeability [82,83]. In 
addition, Faecalibacterium prausnitzii and Bacteroides thetaiotaomicron species 
have been shown to modulate the production of mucus glycans and the 
development of goblet cells [84]. 
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3.3.4. Microbiota role in protection against pathogens 
 
 Gut microbiota plays an essential role in protecting the host against 
potential pathogens by limiting pathogen colonization through competing for 
metabolites and ecological niches within the intestine habitat, in a process 
referred to as colonization resistance [85]. External factors such as diet and 
antibiotics can disrupt the microbiota ecological balance and release 
competitive pressure that will benefic pathogens [85]. This microbiota function 
is well illustrated by the antibiotic-induced Clostridium difficile infection (CDI), 
which prevalence and severity have been increasing in the past two decades 
[86]. CDI can be resolved by fecal microbiota transplantation (FMT) with 
remarkable efficacy, likely by restoring microbial diversity and altering the 
metabolic environment in the intestine of recipient [87]. In fact, specific 
commensal bacteria belonging to XIVa cluster of Clostridia were shown to be 
sufficient to confer resistance to CDI by synthesizing C. difficile-inhibiting 
metabolites from host-derived bile acids [88].  
 
 
3.3.5. Microbiota role in central nervous system 
 
 Gut microbiota is in constant communication with the enteric and central 
nervous system, through bidirectional neural, immune and endocrine pathways, 
the so-called microbiota-gut-brain axis [89]. Over the last decades, a 
tremendous body of evidence has demonstrated the essential role of gut 
microbiota in the development and function of the host brain, and host behavior 
[89]. The earliest descriptions that the gut microbiota could impact brain 
function and behavior arise from the observation that administration of oral 
antibiotics can reverse hepatic encephalopathy [90]. GF mice exhibit altered 
brain chemistry, including the expression of neurotransmitters such as 
noradrenaline (NA), dopamine (DA) and serotonin (5-HT); NMDA and 5-HT 
receptors, as well as brain-derived neurotropic factor (BDNF) [91,92]. 
Additionally, GF mice exhibit an increased response to stress and exploratory 
behavior, as well as learning, memory and sociability deficits [91–94]. Treating 
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mice with antibiotics was also sufficient to trigger changes in brain chemistry 
and behavior, and these changes were reversible upon normalization of 
microbiota [95], or treatment with probiotics and physical exercise [96]. 
Moreover, in an important proof-of-principal experiment demonstrating the 
influence of gut microbiota on host’s behavior, Bercik et al were able to 
modulate the behavior of different mice strains, the timid BALB/c mice and the 
exploratory NIH Swiss mice, by transplanting the gut microbiota from one strain 
to the other. When the microbiota of NIH Swiss was transplanted to the GF 
BALB/c mice, the recipient mice acquired a more exploratory behavior 
characteristic of the NIH Swiss donor. However, GF NIH Swiss mice become less 
exploratory when received microbiota from BALB/C mice [95]. Studies with 
specific probiotics have also showed the dynamics of the microbiota-gut-brain 
axis. Feeding mice with specific beneficial bacteria was shown to modulate brain 
chemistry and ameliorate stress, anxiety and depressive-like behaviors, promote 
social behavior and improve cognitive function [97]. Gut microbiota has been 
also implicated in neuropsychiatry disorders including depression and anxiety, 
autism spectrum disorder (ASD), schizophrenia and Alzheimer’s disease [98]. 
 In addition to CNS, gut microbiota was shown to be important for the 
normal post-natal development of the enteric nervous as demonstrated by a 
decreased in nerve density and abnormal neurochemical composition and 
function of enteric neurons in the small intestine of GF mice [99]. 
 
 
3.4. Factors influencing gut microbiota 
 
 A multitude of endogenous host factors and external factors contribute 
to shaping the gut microbiota composition. Host factors such as genetic 
background [100], gender, body mass index (BMI) [101], age [102], the immune 
response [103], gut function (e.g. gut motility and pH) [33], central factors (e.g. 
stress, mood, psychiatry disorders) [104] and even diurnal rhythm [105] have 
been described to exert influence on the composition of gut microbiota. 
Likewise, environmental factors such as diet [106], xenobiotics (e.g. antibiotics) 
[107], probiotics/prebiotics [108], FMT [109] and life style factors (e.g. smoking) 
General Introduction 
	 21 
[110], and mode of delivery of a neonate [102] were reported to have an impact 
in shaping microbiota composition and function.  
 
 
3.4.1. Genetics 
 
 In the last few years, several studies have attempted to analyze the role 
of host genetics shaping gut microbiota. In particular, three independent 
reports using different large population cohorts published in the same issue in 
Nature Genetics (Nov 2016) have found association between host single 
nucleotide polymorphisms (SNPs) and genomic loci and individual microbiota 
taxonomies and functional pathways [111–113]. However, the fact that even 
highly heritable microbiome traits identified associations have small effect size, 
and recently described concerns about the statistical associations of these 
studies, have raised the question of the true weight of host genetic in 
modulating the microbiota [114–116]. Indeed, a recent study has found limited 
evidence of microbiome-genetic association after analyzing the previous 
published cohorts, and using a new independent cohort [116]. The study 
showed that sharing a common household, not host genetic relationship, 
determines microbiome similarity, and concludes that environmental factors 
dominate over host genetics in shaping human gut microbiota [116].  
 
 
3.4.2. Lifestyle, geography and diet 
 
 To determine how lifestyle, including geographic, ethnic factors and long-
term diet, impacts the gut microbiota, scientists have employed comparative 
population studies between rural communities and industrialized/westernized 
societies. These studies have revealed that industrialization had a profound 
impact on gut microbiota including a decrease in the diversity within the 
individual (α-diversity) and an increased diversity between the individuals (β-
diversity) [117,118], the acquisition and loss of specific gut microbes [119], and 
major shifts in gut metabolic patterns [120]. These differences were mainly 
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attributed to major changes in long-term dietary habits between rural and 
industrial societies. In particular, the high fiber plant-based diet of rural 
communities was shown to favor Prevotella bacteria while low-fiber animal 
based diet typical of industrialized societies favors Bacteroides [117,120–122]. 
 Short-term diet-intervention studies in humans and animals have helped 
corroborating the impact of diet and specific dietary ingredients on gut 
microbiota composition and function. The content of fiber, protein, fat, artificial 
sweeteners, and emulsifying agents have all been reported to modulate the 
diversity and specific microbes of the GI tract [27,123–126].  
 
 
3.4.3. Microbe-microbe interaction 
 
 Gut microbes live in close interaction with each other, either in co-
operative or competitive relationships. For example, certain carbohydrate 
fermentation products such as lactate, succinate and 1,2-propanediol, are not 
usually found in high levels in the human colon of healthy adults, because they 
can serve as substrates for other bacteria, including propionate and butyrate 
producers, a mechanism called microbial cross-feeding [64]. On other hand, 
microbes compete for specific substrates and niches in the GI tract. Indeed, 
specific perturbation of gut microbiota by the depletion (e.g. antibiotics, dietary 
factors) and addition of specific microbial species (e.g. probiotic and FMT 
interventions) will impact the composition of microbiota [127].  
 
 
3.5. Diseases associated with microbiota 
 
 Considering the important role of the gut microbiota in the host’s health, 
it is not surprising that association studies in humans and animals have 
revealed a wide range of dysbiosis-related chronic diseases. These include IBD, 
IBS, celiac disease, colorectal cancer, metabolic disorders (such as diabetes and 
obesity), atherosclerosis, multiple sclerosis, asthma, chronic kidney disease, and 
autism spectrum disorder [128]. Although there has been certain demonstrated 
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causality in some of these associations, many are still based on epidemiological 
and observational studies, with the mechanisms linking the microbiota and the 
host disorders still largely unknown. Adoptive transfer experiments, where the 
gut microbiota is transferred from a human or animal to germ free animals, 
have provided a major contribution to understand causality of the effect of 
microbiota in chronic disorders. Different studies were able to demonstrate that 
transplanting patient microbiota in mice was sufficient to transfer the human 
phenotypes related to obesity [129], Crohn’s disease, Ulcerative colitis [130], IBS 
[131] and MS [132].  
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4. Diet-microbiota interaction in health and disease 
 
 As described above, diet exerts a major influence on gut microbiota 
composition and function. The specific dietary components that arrive as 
substrate to gut microbes, will determine the metabolic pathways that the 
microbes will favor among its enzymatic repertoire. The cocktail of metabolites 
generated will, in turn, have an impact on the dynamics of that specific microbe 
and its “neighbors”, as well as on the host physiology (Fig. 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Diet-microbiota-host interaction. Diet provides substrate to gut microbiota, 
determining microbial metabolic pathways and composition. Host health and disease is affected 
by dietary nutrients and microbial metabolites and MAMPs. SCFA (short-chain fatty acids), 2nd BA 
(Secondary bile acids), Vit. (vitamins), TMAO (Trimethyl amine N-oxide), LPS (Lipopolysaccharide), 
PGN (Peptidoglycan). 
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influences on the host. The beneficial diet-microbiota-host interaction is well 
illustrated by the induction of SCFA-producing bacteria with high fiber diet, and 
consequent production of SCFA, such as butyrate and acetate, with major 
implications for gut homeostasis [6]. Diet-microbiota-host interaction can also 
have a detrimental impact on the host. Trimethyl amine N-oxide (TMAO) is a 
microbial metabolite generated from dietary lecithin and L-carnitine, molecules 
that are enriched in foods such as red meats, eggs, milk and some fish. TMAO 
was found to accelerate atherosclerosis in mice [133,134], and associated with 
increased risk of cardiovascular disease (CVD) in humans [134]. Moreover, 
vegans and vegetarians do not only have lower levels of red-meat derived TMAO 
compared to omnivores, but their microbiota also has a lower capacity to 
synthesize it from ingested carnitine [134]. In a study analyzing the glycemic 
response to semi-standardized diet, Zeevi et al, observed a high inter-personal 
variability for the same foods [135]. Using an algorithm that integrated the 
glycemic response data with clinical and microbial features, the authors were 
able to demonstrate that gut microbiota is an important predictor of the 
glycemic outcome to specific dietary factors. Moreover, the authors were able to 
integrate the microbiota information with other clinical features and design 
personalized diets with beneficial glycemic outcomes [135]. These and other 
examples of diet-microbiota-host interaction (Table 1) provide a strong evidence 
of how gut microbiota plays a key role in mediating the outcomes of diet in host 
health and disease. 	 	
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(See table on previous above) 
Table 1. Evidence of diet-microbiota-host interaction. This table provides examples of studies 
demonstrating microbiota-mediated host phenotypes using diet or pre/probiotic interventions. 
 
 
 
5. Inflammatory Bowel Disease 
 
 
5.1. Epidemiology and etiologies 
 
 
 The inflammatory bowel diseases, Crohn’s disease (CD) and ulcerative 
colitis (UC), are chronic idiopathic disorders causing inflammation of the 
gastrointestinal tract. CD can involve any part of the GI tract in a non-continuous 
fashion and is commonly associated with complications such as strictures, 
abscesses and fistulas. UC is characterized by inflammation that is limited to the 
colon and which usually starts in the rectum. The microscopic features of CD 
include transmural inflammation with thickened submucosa, while in UC 
inflammation is limited to the mucosa and submucosa tissue, with cryptitis and 
crypt abscesses [136]. 
 The prevalence of IBD rapidly increased in the Western world in the 
second half of the twentieth century and is becoming more common in different 
parts of the world that are adopting a Western lifestyle [137]. Epidemiological 
observations indicate that there are strong environmental influences on IBD, 
which is corroborated by the relatively low concordance rate in identical twins 
(50% for CD, and 10% for UC) [138]. Nevertheless, genome-wide association 
studies (GWAS) have found associations between specific genes and genetic loci 
with IBD, many of them involved in intestinal barrier function, epithelial 
restitution, innate and adaptive immune regulation and microbial defense 
[139,140]. The etiology of IBD remains an enigma but it is hypothesized that 
IBD results from an adverse interaction between environmental, host factors and 
genetic susceptibility with gut microbiota playing a key role mediating the 
pathology [136] (Fig. 3). 
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Host	
(Genetic Predisposition)	
(Immune Deregulation)	
Microbiota	
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Figure 3. Interaction of various factors contributing to chronic intestinal inflammation in a 
genetically susceptible host. 
 
  
 Indeed, despite some disparate results, studies assessing gut microbial 
features of IBD patients support the concept that there is a generalized 
reduction in biodiversity (α-diversity) and altered representation of several 
specific bacterial taxa [141]. Moreover, some of the genes with the strongest 
association to IBD, such as NOD2 and genes involved in the differentiation of 
Th17 cells (such as IL-23 and IL-23R), play a key role in gut microbial 
surveillance [142,143]. Recently, it has been shown that transplanting gut 
microbiota from patients with CD to GF mice induced a pro-inflammatory gene 
expression profile in the mice gut that resembles the immunological signatures 
found in CD patients. Furthermore, microbiota of CD patients exacerbated 
experimental colitis in IL-10 deficient mice, a murine model of genetic 
susceptibility to colitis [130].  
 Diet has also been considered as an additional risk factor contributing to 
the etiology of IDB. While no effect was found for the intake of fiber, sugar, 
macronutrients, total energy, vitamin A, C, D, E and carotene on the risk of 
ulcerative colitis, n-6 polyunsaturated fatty acid was identified as a risk factor 
for UC, whilst n-3 polyunsaturated fatty acid may protect against UC. 
Furthermore, high animal protein diet was associated with increased risk of IBD 
and relapses [144]. 
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5.2. Colitis models in mice 
 
 Experimental colitis models have widely served as useful tools for 
understanding the etiology of IBD and the preclinical evaluation of the efficacy 
of new drugs. Several models of acute and chronic intestinal inflammation have 
been developed to simulate various aspects of IBD in humans. Different models 
use very distinct strategies to induce GI inflammation including 1) disruption of 
epithelial barrier, 2) disruption of innate immunity, 3) excessive effector 
immune cell responses, 4) inadequate regulatory response, and others [145]. 
The methodology is also highly variable, including chemical-induced, genetic 
manipulation, pathogen inoculation, immune cells transfer and whole 
microbiota transfer [145]. Each experimental colitis model results in different 
phenotypic outcomes, including immunological and histological features, with 
various degrees of modeling human CD and UC (For a review in colitis models in 
mice, see [145]). 
 In this study, we used two different chemical-induced models, the 
dextran sulfate sodium (DSS) and the dinitrobenzene sulfonic acid (DNBS) 
models. Both models trigger a disruption of the GI tract epithelial layer although 
with different mechanisms of action and phonotypical outcomes. 
 
 
5.2.1. DSS-colitis 
 
 DSS is delivered in drinking water of rodents and results in an 
inflammatory response in the GI tract with the recruitment of M1 macrophages 
and neutrophils to the mucosa. Histologically, DSS colitis induces submucosal 
erosions, inflammatory cell infiltration, erosion of the epithelium and mucosal 
hyperplasia. Mice with DSS colitis will show signs of acute colitis including body 
weight loss, bloody stools and diarrhea, accompanied with the increase in 
mucosal production of pro-inflammatory cytokines IL-6, TNFα and IL1β [146]. 
The damage induced by DSS affects preferentially the colon and the cecum. The 
mechanisms of action are not fully understood but it has been proposed that 
DSS establishes linkages with medium-chain-fatty acids (MCFA) to form vesicles 
General Introduction 
	 30 
that can fuse with colonocyte membranes, leading to a loss of barrier function, 
increased translocation of luminal antigens and activation of intestinal 
inflammatory signaling pathways [147]. The concentration and the number of 
cycles of DSS administration can be customized in order to induce different 
severity degrees of acute colitis and to trigger chronic colitis, respectively [146].  
  
 
5.2.2. DNBS-Colitis 
 
 DNBS is a hapten reagent delivered rectally in the rodent colon which 
induces a localized colonic inflammation. DNBS induces significant body weight 
loss and bloody diarrhea.  The colon damage is characterized by hyperplasia, 
excess of fibrotic tissue and lymphocytic pus, as well as areas of mucosal 
necrosis and typical visible ulcerations. Histological features include a 
transmural necrosis, loss of epithelium and diffuse leukocyte cellular infiltrate in 
the submucosa, namely neutrophils. DNBS is dissolved in a 50% ethanol solution 
to help break the mucosal barrier. The hapten properties will trigger a T cell 
response, including the production of Th1 profile cytokines (IFNγ, TNFα and 
IL12) [146]. 
 
 
 
5. AIMS 
 
 High salt consumption was described to have an impact in modulating 
the immune system in a pro-inflammatory manner, with a direct effect on the 
differentiation and expansion of Th17 cells, and to exacerbate the development 
of MS, both in rodents and humans. 
 Considering that gut microbiota and Th17 T cells play a pivotal role in 
the development of the pathogenesis of IBD, we hypothesized that a diet-
enriched in salt could affect the development of colitis in mice, through the 
modulation of gut microbiota. 
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 First, we characterized the effect of HSD on the composition and 
metabolic pathways of mouse gut microbiota. We proceeded by characterizing 
the impact of HSD on the mucosal immunity of intestinal lamina propria. After 
that, we assessed the effect of HSD on the development of gut inflammation 
using two different models of experimental colitis, DSS and DNBS colitis. Finally, 
using GF mice and gut microbiota transplant experiment, we sought to 
determine whether gut microbiota plays a role in the HSD-induced colitis 
severity. 
 These data open new insights on the potential mechanisms for the 
development of IBD, as well as reveal a new pathway of diet-microbiota-host 
interaction.  
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Lactobacillus levels and butyrate production 
 
  
High diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production 
	 34 
The research work “High salt diet exacerbates colitis in mice by decreasing 
Lactobacillus levels and butyrate production” consists of a first-authorship 
publication. Here is clarified the contribution of each of the authors: 
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The contribution of each author to the publication in clarified as the following: 
 
 
Authors contribution: GDP and PB contributed to develop the study concept and 
design, interpretation and discussion of the results. GDP performed all 
experiments with the GF mice. VS and JM assisted with all immune cell isolation 
experiments, cell-staining and flow cytometry procedures. JL assisted with all 
animal work, including blind colitis and histological assessments. MPLA carried 
out Q-PCR experiments. EFV helped coordinating all GF mice experiments. GDP, 
PB and EFV were major contributors to the critical review of the manuscript. All 
authors read and approved the final manuscript. 
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High salt diet exacerbates colitis in mice by decreasing 
Lactobacillus levels and butyrate production 
 
 
Keywords: Salt, NaCl, Western Diet, Colitis, Microbiota, Lactobacillus, Butyrate, MAPK-
pathway 
 
 
1. Abstract 
 
Background: Changes in hygiene and dietary habits, including increased 
consumption of foods high in fat, simple sugars, and salt that are known to 
impact the composition and function of the intestinal microbiota, may explain 
the increase in prevalence of chronic inflammatory diseases. High salt 
consumption has been shown to worsen autoimmune encephalomyelitis and 
colitis in mouse models through p38/MAPK signaling pathway. However, the 
effect of high salt diet (HSD) on gut microbiota and on intestinal immune 
homeostasis, and their roles in determining vulnerability to intestinal 
inflammatory stimuli are unknown. Here, we investigate the role of gut 
microbiota alterations induced by HSD on the severity of murine experimental 
colitis. 
 
Results: Compared to control diet, HSD altered fecal microbiota composition 
and function, reducing Lactobacillus sp. relative abundance and butyrate 
production. Moreover, HSD affected the colonic, and to a lesser extent small 
intestine mucosal immunity by enhancing the expression of pro-inflammatory 
genes such as Rac1, Map2k1, Map2k6, Atf2, while suppressing many cytokine 
and chemokine genes, such as Ccl3, Ccl4, Cxcl2, Cxcr4, Ccr7. Conventionally 
raised mice fed with HSD developed more severe DSS- (dextran sodium sulfate) 
and DNBS- (dinitrobenzene sulfonic acid) induced colitis compared to mice on 
control diet, and this effect was absent in germ-free mice. Transfer experiments 
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into germ-free mice indicated that the HSD-associated microbiota profile is 
critically dependent on continued exposure to dietary salt. 
 
Conclusions: Our results indicate that the exacerbation of colitis induced by 
HSD is associated with reduction in Lactobacillus sp. and protective short-chain 
fatty acid production, as well as changes in host immune status. We hypothesize 
that these changes alter gut immune homeostasis and lead to increased 
vulnerability to inflammatory insults. 
 
 
2. Background 
 
The prevalence of chronic inflammatory diseases such as multiple 
sclerosis (MS), rheumatoid arthritis, diabetes and inflammatory bowel disease 
(IBD), has been steadily increasing over the past half-century [1]. Although 
multiple genetic factors have been identified to contribute to the risk of 
developing these disorders, genetic drift alone cannot explain the rapid increase 
in prevalence within this relatively short time interval [3]. Therefore 
environmental factors, particularly related to dietary and hygiene habits, have 
been proposed as disease modifiers [5,6]. The relationship between dietary 
habits and the increased prevalence of intestinal inflammatory disorders is of 
particular interest. Consumption of highly-caloric processed foods, high in fat 
and simple carbohydrate content, and low in fiber content, has been steadily 
increasing in the “Western World”, where the incidence of chronic inflammatory 
diseases is the highest [7,8]. Strong epidemiological evidences support the 
concept that diet underpins the rise in chronic inflammatory diseases such as 
IBD, diabetes or asthma [6–8]. However, the exact mechanisms by which specific 
dietary changes increase susceptibility to inflammatory diseases, and whether 
they are indeed mediated by changes in microbiota composition or function, are 
still unclear. Previous studies have shown that a high fat diet may have a direct 
pro-inflammatory effect, increasing the production of pro-inflammatory 
cytokines TNFa, IL-1b and IL-6 [14]. Others have shown direct interactions 
between animal fat consumption, altered bile acid metabolism and specific 
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alteration in the gut microbiota, leading to increased colitis severity [148]. 
However, one characteristic element in the Western diet that has been 
overlooked until recently is its high salt (Sodium Chloride, NaCl) content. 
NaCl has been shown to induce pathogenic Th17 cells (IL-17-producing T-
helper cells) in both human and mice naïve CD4+ cell cultures in vitro. Mice 
receiving a salt-enriched diet developed a more severe form of experimental 
autoimmune encephalomyelitis (EAE), an animal model of MS, mediated by IL-
17A and RORγt expressing Th17 cells [21,22]. Interestingly, high NaCl intake 
has been associated with increased disease activity in MS patients [149]. 
Moreover, a longitudinal clinical study showed that high NaCl intake increases 
circulating monocytes and levels of plasma cytokines such as IL-6 and IL-23 [26]. 
A recent study has shown that exposing human lamina propria mononuclear 
cells (LPMC) to high concentrations of NaCl enhances TNF-a and IL-17A release 
in a p38-dependent manner, and that feeding mice a salt-enriched diet 
exacerbates experimental colitis [150]. While all these studies suggest a 
promoting role of high salt diet in driving a pro-inflammatory state, the 
underlying mechanism are still not fully understood. 
We hypothesized that a high salt diet impacts inflammation via the 
interaction with the gut microbiota. In fact, it is well established that diet 
determines the composition [48,117,151] and function [152,153] of the gut 
microbiota. It has been recently shown that diet low in dietary fiber may be 
causing irreversible changes in gut microbiota with some species disappearing 
over generations [154]. Given that gut microbiota composition has been 
implicated in the pathophysiology of multiple immune-related disorders, such as 
IBD, diabetes or asthma[155], and taking into account that diet shapes the gut 
microbiota, we investigated the ability of high salt diet (HSD) to modulate gut 
microbial composition and metabolism, and to influence vulnerability to 
intestinal inflammatory stimuli. 
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3. Materials and Methods 
 
Mice  
 
 Six- to eight-week old specific pathogen free (SPF) male C57BL/6 mice 
(obtained from Taconic) were housed at the animal facility of McMaster 
University under 12h light/dark cycles and standard conditions for temperature 
and humidity. All mice received irradiated control diet (7004, Teklad, with 20% 
of calories from protein, 29% from fat and 51% from carbohydrates, containing 
0.4% Na and 0.7% Cl) and sterile tap water ad libitum upon arrival. Experiments 
started one week after arrival in the central animal facility, to allow the animals 
to habituate to the novel environment. Mice were then divided into 2 groups: 1) 
Control diet - mice were fed with control diet for the entire course of the 
experiment; 2) HSD (High Salt Diet) - mice received the same diet supplemented 
with 4% NaCl (custom ordered from Teklad), plus 1% NaCl sterile water, ad 
libitum, during 4 weeks. For germ-free (GF) mice experiments, C57BL/6 mice 
were re-derived in McMaster Axenic Gnotobiotic Unit (AGU) by two-stage embryo 
transfer and kept in dedicated isolators during the entire course of the 
experiment. For the microbiota-transfer experiment, GF mice were colonized by 
oral gavage with 200ml of cecal microbiota from a mouse fed with control diet 
or HSD and housed in dedicated individually ventilated racks.  
 
DNA isolation and 16S rRNA Illumina sequencing 
 
 DNA was extracted from 100mg of fecal content samples using the 
MagMAX DNA Multi-sample kit and the MagMAX Express-96 well magnetic 
particle processor (Thermofisher, Waltham, MA) to achieve an automatic and 
standardized DNA extraction across samples. Briefly, fecal samples were 
mechanically homogenized with 2.8 mm ceramic beads (MoBio, Carlsbad, CA, 
USA; an additional 0.2 g of 0.1 mm glass beads were added), 100 ml of 
guanidine thiocyanate-EDTA-N-lauroyl sarcosine and 800 ml of 200mM NaPO
4
. 
Samples were homogenized for 3 min at 300 rpm and centrifuged 5 minutes at 
maximum speed. 200 ml of the extract was added to the MagMAX Express plate 
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for further DNA extraction procedures according to manufacturer’s instructions. 
Isolated DNA was kept at -20º C (or -80º C for longer storage). Polymerase Chain 
Reaction (PCR) amplification of the variable 3 (V3) region of the 16S rRNA gene 
was preformed as previously described [156,157]. Purified PCR products were 
sequenced using the Illumina MiSeq platform by the McMaster Genomics facility. 
Of note, we lost two samples during processing, one from Baseline group and 
one from 4 Weeks HSD group. 
 
Illumina sequencing processing and analysis 
  
 Custom, in-house Perl scripts were developed to process the sequences 
after Illumina sequencing [158]. The sl1p pipeline is open source and publicly 
available at https://bitbucket.org/fwhelan/sl1p. Briefly, Cutadapt [159], was 
used to trim any over-read, and paired-end sequences were aligned with 
PANDAseq [160], with a 0.7 quality threshold. If a mismatch in the assembly of 
a specific set of paired-end sequences was discovered, they were culled. 
Additional, any sequences with ambiguous base calls were also discarded. 
Operational taxonomic units (OTUs) were picked using AbundantOTU+ [161], 
with a clustering threshold of 97%.  Taxonomy was assigned using the 
Ribosomal Database Project (RDP) classifier v.2.2 [162] against the Greengenes 
SSU reference database (2013 release) [163]. For all downstream analysis we 
used Quantitative Insights Into Microbial Ecology (QIIME) [164]. We obtained a 
total of 2,839,134 reads after quality filtering, with an average of 76,733.351 
reads/sample (range: 34,470 to 144,746). OTU tables were filtered to exclude 
“Root” and any OTU with less than 10 sequences in all samples, and finally 
rarefied to 30,000 reads/sample. Calculations of within-community diversity (a-
diversity), between-community diversity (b-diversity), relative abundance 
taxonomic summaries, and the different statistical analysis were preformed 
using QIIME (scripts “alpha_rarefaction.py” and 
“beta_diversity_through_plots.py”, respectively). The relationships between HSD 
and microbiota phylogeny were explored using Principal Coordinate analysis on 
unweighted unifrac metrics and abundance jaccard index 
(“beta_diversity_through_plots” script, QIIME), and the dissimilarity distance 
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between the diet groups was tested using ANOSIM statistical method 
(“compare_categories” script, QIIME). For relative abundance taxonomic 
summaries and further statistical analysis, OTUs with a representation of less 
than 0,1% in the community were excluded. The correlations between fecal 
microbiota composition (at the highest taxonomic levels (family and genus) and 
at OTU level) and the diet, were assessed by Spearman’s rank correlation 
coefficient with fisher z-transformation P-value assignment method, using the 
“observation_metadata_correlation” script (QIIME), based on the attribution of a 
ranked value to the variable “Weeks of NaCl in diet”, from “0” to “4”. The “Wash 
Out” group was ranked “0”. PICRUSt [165] was used to predict the altered KEGG 
pathways based on the 16S sequencing data. L3 KEGG pathways correlation with 
length of HSD was calculated based on Spearman’s correlation using Prism 
GraphPad 6 (GraphPad software). Heatmaps were generated using the 
Heatmaps2 package (gplot) for R (version 3.3.2). In the microbiota-transfer 
experiment, the OTUs were considered successfully transferred when present 
with an average of 2 reads or higher. 
 
 
Short-Chain Fatty Acids (SCFA) quantification 
  
 SCFA were quantified as previously published [166,167]. Briefly, 20-50 
mg of frozen cecal content was collected into a tube, previously treated with 
methanol. The cecal samples were diluted 1:1 (w:v) with HCl 3.7% (10X diluted) 
and homogenized. Then 10 ml of internal standards and 500 ml of diethyl ether 
were added to the samples, and the tubes vortexed for 15 min. The extract (400 
ml) was transferred to a clean tube. This step was repeated until we obtained a 
total of 800 ml of diethyl ether-fecal extract, 60 ml of which was then 
transferred to a chromatographic vial with 20 ml of N-tert-butyldimethylsilyl-N-
methyltrifluoroacetamide (MTBSTFA). The organic extract-MTBSTFA was 
incubated at room temperature for at least 1 hour, before being analyzed using 
the GC-MS Agilent 6890N GC coupled to Agilent 5973N Mass Selective Detector, 
with the column DB-17HT (30m x 0.25 mm ID, 0.15 mm film).  
 
High diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production 
	 42 
Experimental colitis  
  
 Additional groups of six- to eight-week old specific pathogen free (SPF) 
male C57BL/6 mice (obtained from Taconic) and NIH Swiss mice (obtained from 
Harlan) were housed at the animal facility of McMaster University as described 
above. After a period of 4 weeks on HSD or Control Diet, mice were given 3.5% 
Dextran Sodium Sulfate (DSS, MW 36-50kDa; MP Biomedicals, Santa Ana, CA) in 
drinking water for 5 days, followed by regular water for the next 2 days. HSD 
mice were switched to control diet before starting DSS administration. Body 
weight and general health condition were assessed daily. At day 7, mice were 
euthanized and the colon was blindly evaluated using a previously validated 
score [168,169]. Briefly, the colon was evaluated for muscle thickness, 
hyperemia and erythema, presence of blood in the stools, and stool formation 
(For details, see Supplementary Methods). Control mice (no DSS) received only 
water during the entire procedure. For germ-free (GF) mice, the DSS dose had to 
be lowered to a 2% solution due to their higher sensitivity to experimental 
colitis. For the microbiota adoptive transfer experiments in ex-germ free mice a 
2.5% DSS solution was used, starting 5 days after colonization.  
 For Dinitrobenzene sulfonic acid (DNBS)-colitis, mice were anesthetized 
with isoflurane (3%) and injected with 1 ml of saline subcutaneously. A custom-
made polyester catheter was introduced 3.5 cm into the rectum and 100 ml of 
50% EtOH containing 3.5 mg of DNBS (MP Biomedicals, Santa Ana, CA) was 
injected. From that day, all mice received control diet with normal water 
containing 6% sucrose to prevent dehydration. At day 3 post DNBS, mice were 
euthanized and blindly evaluated using a validated DNBS-colitis macroscopic 
score [170]. The colon was evaluated for adhesion to surrounding tissue, 
thickness, hyperemia, erythema, and stool consistency. Mucosal ulcers were 
quantified and measured (for details see Supplementary Methods). Mice from 
control group (no DNBS-colitis) were rectally injected with a 50% EtOH solution.  
 
Tissue processing 
 
 Blood was collected via orbital bleeding and centrifuged at 5000 rpm, for 
10 minutes. The serum was separated and stored at -80º C. The colon (full 
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length, from the rectum to the cecum) was excised and measured. Colonic 
content was removed and 0.5-1.0 cm sections were dissected from mid-colon 
and either snap-frozen in liquid N
2 
for MPO analysis, stored in RNA later 
(Ambion) for RNA extraction or fixed in 10% buffered formalin for histology 
assessment (from the border of an ulcer when present). MPO was performed on 
frozen tissues as previously described [171] and its activity expressed in units 
per milligrams of tissue. For histology, colonic sections were embedded in 
paraffin, 48 hours after being fixed in 10% formalin solution, and stained with 
haematoxylin and eosin (H&E). Inflammation was blindly evaluated following an 
inflammation histology scoring system (see Supplementary Materials). 
 
Gene Expression 
 
 Total RNA was extracted and purified using RNeasy Mini Kit (Qiagen, 
Hilden, Germany), according to manufacturer’s instructions, including the DNA 
removal step using the RNase-Free DNase Set (Qiagen). NanoString nCounter 
Gene Expression CodeSet for mouse inflammation genes (v2; 248 genes) and a 
custom CodeSet panel that included 68 genes related to immune, gut barrier 
and neurobiology functions (see Supplementary Materials); were run according 
to manufacturer’s instructions (NanoString Technologies Inc., Seattle, WA). Data 
from nCounter was analyzed using nSolver 2.5 software (Nanostring 
Technologies Inc.). The log2 ratios of gene expression were then uploaded into 
Ingenuity Pathway Analysis software (Qiagen) for further analysis. For Q-PCR 
gene expression, cDNA library was generated using the SuperScript III First-
Strand Synthesis System (Invitrogen, Carlsbad, CA), according to manufacturer’s 
instructions, using Oligo-dT primers (Qiagen). Additional information on the 
primers is provided in supplementary materials. 
 
Immune Cells Extraction 
 
 Mesenteric lymph nodes (mLN) were harvested aseptically and the cells 
were released from the nodes using a 70 mm strainer with the help of a syringe 
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plunger, and suspended in RPMI medium. After washing, the cells were kept in 
complete RPMI medium on ice until further use.  
 Colonic and small intestinal (SI) lamina propria (LP) cell extraction was 
performed using established protocols [172]. Briefly, colon and SI were removed 
and kept in cold sterile Dulbecco’s phosphate buffered (DPBS) solution until 
further processing. All fatty tissue, content and the payer’s patches were 
removed. Sections of intestine were open longitudinally, cut into 0.5-1 cm 
pieces and incubated in 2 mM Dethiothreitol (DTT)/Hank’s solution (HBSS), on a 
horizontal shaker (240rpm) for 15 minutes at 37º C to remove the mucous 
layer. After vigorous vortexing, the tissues were strained with a sterile metal 
strainer and incubated with a 5 mM EDTA/HBSS solution for 10 minutes at 37ºC 
(240rpm) to remove the epithelial layer. After vigorous vortexing, the tissues 
were strained once again. This epithelial removal step was repeated 3-4 times. 
After removing the EDTA solution, the tissues were digested in 0.1% 
Collagenase solution (Type VIII; Sigma-Aldrich, St. Louis, MO) and DNAse (I 
recombinant, Grade I; Roche, Basel, Switzerland; 0.05mg/50ml of digestion 
solution) to aid the release of the LP cells (15 minutes for SI and 25 min for 
colon, 37º C). Supernatants were strained through a 40 mm cell strainer to 
separate LP cells from the remaining intestinal tissue, and washed thoroughly. 
The cell suspension was then purified by Percoll (GE Healthcare, Chicago, IL) 
density gradient method. Briefly, the cell suspension was re-suspended in 35% 
Percoll solution and underlayed with a solution of 70% Percoll. The tubes were 
centrifuged at 4º C, 670 G, for 30 minutes (without break and with slow 
acceleration). The purified cell suspension was removed from the interphase, 
washed and resuspended in complete RPMI. For LP cells gene expression, the 
cell suspension was resuspended in RLT buffer (RNeasy Mini Kit, Qiagen) and 
snap frozen in liquid nitrogen. 
 
Flow Cytometry 
 
 Cells isolated from mLNs, colon LP and SI LP were divided into two groups 
for intracellular staining: 1) anti-IL17A + anti-RORgt; and 2) anti-FoxP3. Cells of 
the first group were stimulated for 4-5 hours at 37º C with PMA (50 ng/ml), 
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ionomycin (750 ng/ml; both from Sigma-Aldrich), in the presence of 10mg/ml of 
Brefeldin A (BD Biosciences, San Jose, CA), to activate IL17A expression. After 
this period, all cells were washed with PBS solution and stained for cell viability 
with Fixable Viability Dye eFluor® 780 (1:1000; eBiosciences, San Diego, CA) for 
30 minutes at RT. Cells were then stained with the following extracellular 
antibodies: anti-TCRb-PerCP-Cy5.5 (1:100; H57-597 clone; eBioscience) and anti-
CD4+-Pacific Blue (1:200, RM4-5 close, BD Biosciences), for 30 minutes at 4º C. 
Cells were fixed and permeabilized with FoxP3 Fixation/Permeabilization 
Concentrate and Diluent (eBioscience), according to manufacturer’s instructions, 
and stained for 90 minutes at 4º C, with the following intracellular antibodies: 
anti-IL17A-APC (1:100; TC11-18H10.1 clone, Biolegend, San Diego, CA) and anti-
RORgt-PE (1:100; AFKJS-9 clone; eBioscience); or anti-FoxP3-FITC (1:100; FJK-16s 
clone; eBioscience). The data was acquired on LSR II cytometer (BD Bioscience) 
and analyzed with FlowJo software (10.2 version) (TreeStar, Ashland, OR).  
 
Statistical Analysis 
  
 Data analysis was carried out using GraphPad Prism 6 (GraphPad 
Software, La Jolla, CA). Student’s t-test, multiple t-test, one-way ANOVA or two-
way ANOVA, were used as appropriate. For ANOVA, samples were corrected for 
multiple comparisons using Tukey’s test. For Nanostring data, including 
heatmaps, the statistical analysis was carried out using nSolver 2.5 software 
(Nanostring Technologies). Heatmaps were generated using Euclidean distance 
metric based on group average. P<0.05 was consider as statistically significant. 
Values are presented as means ± SEM. 
 
 
4. Results 
 
HSD alters gut microbiota composition 
  
 To investigate the impact of HSD on gut microbiota composition, we 
analyzed intestinal microbiota dynamics of mice fed HSD for 4 weeks, with a 
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follow-up at 1 week after the mice returned to the control diet. While fecal 
bacterial richness (observed species) and diversity (Chao1 diversity index) were 
not affected during the HSD, both a-diversity metrics decreased at 1 week 
follow-up (Supplementary Fig. 1). Despite some variability within groups, we 
observed a significant modulation of fecal bacteria composition with time 
exposure to HSD, based on the phylogenetic distance metric unweighted unifrac 
(UnwUF) and the non-phylogenetic abundance weighted Jaccard distance (AJac) 
(ANOSIM of UnwUF: R=0.416, p=0.001; ANOSIM of AJac: R=0.283, p=0.003) (Fig. 
1A, Table 1). One week of HSD was not sufficient to significantly modulate the 
microbiota but 4 weeks of HSD led to a significant shift in the composition, as 
revealed by ANOSIM pairwise analysis (UnwUF: R=0.480, p=0.004; AJac: 
R=0.036, p=0.008; Table 1). Interestingly, 1 week after returning to the control 
diet, fecal microbiota composition partially reverted to its original composition, 
based on unweighted and weighted unifrac metrics (Fig. 1A, Table 1 and 
supplementary fig. 2).  
 
 
Table 1: ANOSIM statistical analysis of distance metrics on the effect of HSD on 
fecal microbiota composition 
 
  
  
  Unweighted Unifrac   
Abundance Jaccard 
Index 
 
ANOSIM R ANOSIM p 
 
ANOSIM R ANOSIM p 
All Groups 0.416 0.001   0.283 0.003 
Baseline vs 1 Week HSD 0.144 0.133 
 
0.211 0.108 
Baseline vs 4 Week HSD 0.48 0.004 
 
0.36 0.008 
Baseline vs Wash Out 0.341 0.034 
 
0.197 0.106 
1 Week HSD vs 4 Week HSD 0.277 0.052 
 
0.528 0.006 
4 Week HSD vs Wash Out 0.525 0.007   0.075 0.237 	
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Figure 1. (See legend on next page) 
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Figure 1. High salt diet alters gut microbiota composition and function. A: Principal coordinate 
analysis (PCoA) plots of unweighted unifrac metric (left panel) and abundance jaccard index (right 
panel) of fecal microbiota composition over time exposed to HSD. Grey arrows indicate the 
direction of the significant microbiota composition shifts between groups B: Summary of the 
relative abundance of microbial genera present in 99.9% of the community over time exposure to 
HSD. C: Relative abundance of fecal bacterial genera (left panel) and OTUs (right panel) that 
significantly correlate with HSD (q < 0.05). The blue background represents the period exposed to 
HSD. D: Heatmap of the 20 most significant KEGG pathways that correlate with HSD in fecal 
microbiota. E: SCFA quantification, at 0 and 4 weeks after HSD. Un. G (Unclassified Genus). AA 
(acetic acid), PrA (propionic acid), IbuA (isobutyric acid), BA (butyric acid), IvaA (isovaleric acid), 
PeA (pentanoic acid), LA (lactic acid). Values are presented as means ± SEM. n= 5-6 mice/group. * 
(p < 0.05). 
 
 
 
 In order to better understand the impact of HSD on the microbial 
community, we studied the correlation between HSD exposure and the 
taxonomic composition at genus and OTU level. Four bacterial genera were 
found to significantly correlate with HSD (Fig. 1B-C, Table S1). Lactobacillus 
genus showed the strongest correlation by decreasing 2-fold of its relative 
abundance after 4 weeks of HSD and quickly normalizing after returning to the 
control diet (r=-0.703, q=0.003). An unclassified genus belonging to the order 
Clostridiales also decreased relative abundance over 1-fold after 4 weeks of HSD 
and partially normalized 1 week after returning to control diet (r=-0.605, 
q=0.017). Finally, unclassified genera belonging to the Lachnospiraceae family 
and the Oscillospira genus showed a positive correlation with HSD (r=0.614, 
q=0.017 and r=0.548, q=0.042, respectively) (Fig. 1B-C, Table S1). Similarly, 
three fecal OTUs correlated with time of exposure to HSD (Fig 1C, Table S2): 
OTU #3, belonging to the genus Lactobacillus (r =-0.707, q=0.005), OTU #9, 
belonging to the order Clostridiales (r=-0.684, q=0.005), and OTU #25, 
belonging to the family Lachnospiraceae (r=0.609, q=0.027).  
 To test the stability of fecal microbiota and rule out spontaneous changes 
in microbial profiles during this age period, we analyzed microbiota 
composition in an additional group of control mice fed with control diet. There 
were no spontaneous changes in the microbiota genus affected by HSD such as 
High diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production 
	 49 
Lactobacillus, Oscillospira and unclassified genus from Clostridiales and 
Lachnospisaceae, between week 8 and 12, in mice on control diet 
(Supplementary Fig 3). However, the microbiota profiles of mice on HSD and 
control diet clustered separately at both time points, likely consequence of the 
cage effect and low number of mice (Supplementary Fig. 3). 
 
 
HSD affects predicted microbial metabolic activity and luminal SCFA levels 
 
 To investigate whether the differences in fecal microbiota composition 
induced by HSD could impact its metabolic activity, we assessed inferred 
metagenomic KEGG pathways, using PICRUSt [165]. Multiple pathways appeared 
to be affected, with three of them being strongly upregulated by HSD, including 
“fatty acid metabolism”, “lysine degradation” and “arginine and proline 
metabolism”, while “fructose and mannose metabolism” was down-regulated 
(Fig 1D). As HSD altered the relative abundance of several OTUs and genera of 
major SCFAs producers such as Lachnospiraceae, Clostridiales and Oscillospira, 
and PICRUSt predicted changes in the metabolism of fatty acids, we sought to 
quantify luminal SCFA in mice on HSD. Out of the seven SCFA tested, only 
butyrate levels were significantly affected, showing a decrease after 4 weeks of 
HSD (Fig. 1E). We also observed a decrease in lactic acid concentration, however 
this change did not reach statistical significance. Taken together, these results 
show that HSD modulates both composition and function of the gut microbiota. 
 
 
HSD modulates colonic and small intestinal immune gene expression  
 
 We subsequently tested whether the HSD-induced changes in gut 
microbiota were affecting host’s gut mucosal homeostasis. We assessed gene 
expression profile of colonic lamina propria immune cells with nCounter Mouse 
Inflammation V2 Panel (Nanostring). HSD altered the expression of 35 genes 
(p<0.05) in mouse colonic lamina propria cell extract, with 11 transcripts being 
significantly upregulated and 24 being downregulated (Fig. 2A-B; See Table S3 
for the full list of affected genes). Some of these genes were selected for 
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validation by q-PCR (Fig. 2C). A considerable part of the affected transcripts 
were chemokines, cytokines or their receptors (Table S3). Among these, the 
cytokine IL-7 and the receptor IL-1rap were upregulated by HSD (0.47 and 0.19 
log2 ratio, respectively), while all other cytokines and chemokines were down-
regulated. Of note, we observed the downregulation of several chemokines (and 
chemokine receptors) important for the chemotaxis of 
monocytes/macrophages, dendritic cells, neutrophils, and NK cells, such as 
Ccl3, Ccl4, Cxcl10, Cxcl2, Ccr7 and Cxcr4 (Table S3), indicating a possible 
impairment of their migration. The most significant change observed was the 
upregulation of Rac1 (Ras-related C3 botulinum toxin substrate 1) transcript 
(log2 ratio=0.41, p=0.0001), a member of Rho family GTPases with broad 
functions, from innate immunity processes to leukocyte chemotaxis and barrier 
function.  
In order to identify possible functional pathways affected by HSD we 
integrated our gene expression data with publicly available databases results 
using Ingenuity Pathway Analysis (IPA) bioinformatics platform. The 
upregulation of the genes Map2k6, Map2k1, Mapk3, Atf2 and IL1rap was 
predicted by IPA to stimulate several pro-inflammatory canonical pathways such 
as “Acute phase response signaling”, IL-6 and Mapk signaling (Table S4). The 
role of Macrophages and IL-17 signaling were also strongly predicted to be 
affected by HSD (Table S7). Even though IL-17A cytokine itself was not found to 
be significantly affected by HSD in lamina propria colonic cell extracts, IPA 
identified multiple genes related to IL-17 signaling to be affected, such as 
Mapk3, Map2k1, Map2k6 and the transcription factor Atf2 (all upregulated), as 
well as Cxcl10, Hras and Ptgs2 (all downregulated). When analyzing functions 
affected by HSD in the colon, IPA predicted downregulation of leukocyte 
migration and movement (Fig. 2D, Table S5). This was expected since HSD 
suppressed the expression of many chemokines and cytokines responsible for 
immune cells chemotaxis. On the other hand, the functions related to leukocyte 
viability and maturation were predicted to be upregulated, based on the 
expression of genes like IL-7, Map2k1 and Mapk3 (Fig. 2D, Table S5). 
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Figure 2. (See legend on next page) 
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Figure 2. High salt diet modulates immune expression in colonic lamina propria. A: Volcano 
plot of gene expression in colonic lamina propria total cell extract of mice receiving HSD or 
control diet for 4 weeks, n=9 mice/group. Pink dots: genes with p < 0.01. Blue dots: genes with 
0.01 < p < 0.05, fold change > 2. B: Heatmap of immune genes that changed with HSD (p<0.05). 
Based on groups average, euclidean distance metric. C: qRT-PCR analysis of differentially 
expressed genes in the two groups. Values are presented as means ± SEM; n= 5-6 colon/group; * 
(p<0.05) ** (p<0.01) # (p<0.001) g (p=0.065). D: Gene-cell function networks obtained from 
Ingenuity Pathway Analysis. On the left, network with the genes that contribute to the predicted 
inhibition of functions related to immune cell migration, and, on the right, network with the genes 
that contribute to the predicted upregulation of the immune cell viability and maturation. 
 
 
 
Although the focus of our study was the effect of HSD on colonic 
microbiota and immune function, we also assessed its effect on small intestine 
recognizing that that most of the Na+ and Cl- is absorbed in this compartment. 
We observed a significant change in the expression of 11 genes (p<0.05), 
including the upregulation of IL17A and Defa-rs1, as well the downregulation of 
IL12a and Cxcr4 (Supplementary Fig. 4, Table S6). Only 2 genes (Cxcr4 and 
Mef2c_Mm) were affected similarly in both colonic and small intestinal lamina 
propria cell extracts, emphasizing the distinct nature of the immune milieu of 
each gut compartment. IPA identified three canonical pathways related to 
bacteria recognition, toll-like receptors and IL-17 signaling to be most affected 
in the small intestine (Table S7). While “recruitment of leukocytes (z=0.196, 
p=4.01E-05) was upregulated, “proliferation of lymphocytes” (z=-2.398, p= 
5.44E-06) was downregulated. 
 
 
HSD increases RORgt+IL17+ T-cells in mLNs but not in intestinal lamina 
propria  
 
 To better understand the effect of HSD on lymphocyte function, we 
phenotyped T cell populations in the small intestinal and colonic lamina propria 
and in mesenteric lymph nodes (mLNs) using flow cytometry. HSD led to a 2-fold 
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increase of RORgt+IL17A+ cells in the mLNs but not in small intestinal or colonic 
lamina propria (Supplementary Fig. 5A). However, we consistently observed a 
mild but not statistically significant increase of this cell population in the colon 
across all experiments. No change was observed in the expression of IFNg by 
CD4+ T cells in mice on HSD (data not shown), nor in the frequency of 
CD4+FoxP3+ T cells, even though, for the latter, we noticed a small increase of 
this cell type across tissues in all experiments (Supplementary Fig 5B). Taken 
together, these results show that HSD affects the gut mucosal immune 
compartment. 
 
 
HSD exacerbates DSS colitis 
 
 To investigate how the changes in gut microbiota and immune function 
affect vulnerability to inflammatory insults, we used DSS and DNBS colitis 
models. We confirmed that mice on HSD developed a more severe DSS colitis 
when compared to mice on control diet, as previously described[150], 
characterized by an increased rectal bleeding, diarrhea, and general 
inflammation of the colonic tissue (Fig. 3A). HSD induced higher weight loss on 
day 5 of DSS administration, when compared to DSS mice on control diet, a 
difference that was maintained until the end of the experiment, on day 7 (Fig. 
3B), indicating an accelerated onset and increased severity of colitis. Colon 
shortening, normally used as indicator of colitis severity, was greater in HSD 
mice compared to control diet mice (Fig 3C). MPO activity, reflecting neutrophil 
infiltration, was increased 2-fold in the colon of mice on HSD after DSS 
administration, when compared to mice on control diet (Fig. 3D). Furthermore, 
there was a significant difference in mortality between the two groups, with 5% 
of mice on control diet meeting the endpoint criteria prematurely, while this 
number increased to 19% in mice on HSD (Fig. 3E).  
To better understand the immune responses during DSS colitis, we 
assessed the expression of a group of genes related to immune and barrier 
function using a customized Nanostring gene expression codeset (See list of 
genes in supplementary methods). HSD altered the expression of 9 genes in the 
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colon of mice on DSS, when compared to DSS mice on control diet (Fig. 3F). HSD 
decreased expression of genes involved in the maintenance of mucosal barrier 
such as Tjp1 (tight junction protein ZO-1), Muc2 (Mucin 2), Tff3 (trefoil factor 3) 
and Ocln (Occludin). On other hand, HSD mice had an increased expression of 
MMP9 (Matrix Metalloproteinase 9) and Cnlp (Cathelcidin-related antimicrobial 
peptide), genes expressed by innate immune cells such neutrophils and 
macrophages and previously described to be over-expressed in gut 
inflammatory conditions [173,174]. HSD also reduced expression of two genes 
strongly expressed by epithelial cells: F2rl1 (protease activated receptor 2) and 
5-HT (serotonin). This finding might be a consequence of the severe epithelial 
damage observed in colitis. Thus, the altered gene expression profile supports 
the notion that HSD exacerbates DSS colitis. 
These results were reproduced using another mouse strain; NIH Swiss 
mice also developed a more severe DSS colitis after 4 weeks of HSD, confirming 
that HSD induces susceptibility to experimental colitis in multiple mouse strains 
(Supplementary Fig. 6). 
 
 
HSD exacerbates DNBS-colitis  
 
To confirm the increased sensitivity to colonic inflammation in mice on 
HSD, we used the DNBS model. Similar to the DSS colitis model, we chose a 
concentration of DNBS that would induce a mild form of colitis (3.5mg of 
DNBS/mouse), in order to appreciate the effect of diet on worsening of 
experimental colitis. Similar to the results obtained with DSS-induced colitis, 
mice that were previously exposed to a 4-week HSD developed more severe 
colitis after rectal injection of DNBS (Fig. 4A). HSD mice had higher number of 
ulcers that were larger in size, when compared to control diet mice. Fig. 4B-C 
shows that HSD mice developed ulcers that affected the entire colonic wall, up 
until the serosa with large clusters of cellular infiltrates, and, in some cases, a 
total loss of the epithelial layer.  Strikingly, while none of the control diet mice 
met the endpoint criteria to be euthanized at this mild DNBS concentration, the 
mortality of HSD mice after DNBS administration reached 25% (Fig. 4D). Taken 
together, these results show that HSD exacerbates both, DSS- and DNBS-colitis. 
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Figure 3. (See legend on next page) 
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(See Figure on previous page) 
Figure 3. High salt diet exacerbates DSS colitis. A: DSS colitis macroscopic scores at endpoint 
(day 7) in four groups of mice: Control (control diet, no DSS), HSD (high salt diet, no DSS), 
Control+DSS (control diet, DSS in water), HSD+DSS (high salt diet, DSS in water). B: Body weight 
changes during DSS administration. C: Colon length at endpoint. D: Colonic MPO of the two 
groups of mice receiving DSS. E: Survival curve of the two groups of mice with DSS colitis. F: 
Heatmap of differentially expressed genes (p<0.05) in the colon of mice with DSS colitis: C+D 
(Control diet+DSS), HS+D (HSD+DSS). The heatmap was generated based on group average, using 
Euclidean distance metric. Colitis scores, weight change, colon length and MPO are presented as 
means ± SEM; n = 8-9 mice/group. * (p<0.05) ** (p<0.01) # (p<0.001) ## (p<0.0001). 
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Figure 4. High salt diet exacerbates DNBS colitis. A: DNBS colitis macroscopic scores at 
endpoint (day 3) in four groups of mice: Control (control diet, 50% EtOH vehicle), HSD (high salt 
diet, 50% EtOH vehicle), DNBS (control diet, DNBS in 50% EtOH vehicle), HSD+DNBS (high salt diet, 
DNBS in 50% EtOH vehicle). B: Representative H&E-staining of colonic section of DNBS mice 
highlighting the ulcers in the mucosa. C: Histological scores in colonic sections. D: Survival curve 
of the two groups with DNBS colitis. Colitis and histology scores are presented as means ±S EM; 
n= 5-9 mice/group. * (p<0.05) ** (p<0.01) # (p<0.001) ## (p<0.0001). 
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HSD exacerbates experimental colitis in a gut microbiota-dependent manner 
 
We hypothesized that 
HSD exacerbates colitis through 
induction of gut dysbiosis as it 
decreases levels of beneficial 
bacteria, such as Lactobacillus, 
and decreases butyrate, a SCFA 
important for gut immune 
homeostasis and previously 
shown to be protective in colitis. 
To test this hypothesis, we 
administered 2% DSS to germ-
free (GF) mice after 4 weeks of 
HSD. DSS administration induced 
colitis in GF mice (Fig. 5A-B), 
with increase in macroscopic 
scores and decreased colon 
length compared to control mice 
not exposed to DSS. However, 
there were no differences in 
macroscopic scores, colon 
length, MPO or histology scores 
between GF mice on HSD and 
those on control diet after DSS-
colitis (Fig. 5 A-D). We assessed 
the expression of a group of 
relevant genes using a 
customized Nanostring gene 
expression codeset.  
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(See figure on previous page) 
Figure 5. The effect of high salt diet on exacerbation of colitis is dependent on gut 
microbiota. A: DSS colitis macroscopic scores at endpoint (Day 7) in three groups of mice: Control 
(no DSS colitis), DSS (control diet, DSS in water), HSD+DSS (High salt diet, DSS in water). B: Colon 
length of mice at endpoint. C: Colonic MPO. D: Histological scores of the DSS colitis. Values are 
presented as means ± SEM; n= 3-6 mice/group. * (p<0.05) ** (p<0.01). E: Heatmap of the gene 
expression of 68 genes related to immune, gut barrier and neural function, in the colon tissue of 
germ-free mice after DSS administration, on control diet or HSD: C+D (control diet + DSS), HS+D 
(HSD+DSS). The heatmap was generated based on group average, using Euclidean distance metric. 
 
 
 
DSS administration altered expression of 25 genes in GF mice on control 
diet (Table S8) that were related to immune, barrier and neural function such as 
Mapk1, Nfkb1, CD11c and GABA B, confirming that the administration of DSS 
altered gut physiology, even in the absence of microbiota. However, out of the 
68 tested genes, only one gene, Reg3ɣ, was found to be differentially expressed 
between HSD and control diet groups after DSS administration (log2 ratio=-1.15; 
p=0.032). These results suggest that the colonic microbiota is a key factor in 
exacerbation of colitis by HSD.  
To test whether HSD-associated microbiota alone can confer increased 
vulnerability to inflammatory insult, we transferred the microbiota from mice on 
HSD or control diet to GF mice. The recipient mice received control diet during 
the entire course of the experiment and were exposed to 1 cycle of DSS, starting 
at day 5 post-colonization (Fig 6A). We observed no differences in colitis 
severity, including weight loss, colon length and macroscopic scores between 
the two groups of mice (Fig 6F-H). However, when analyzing the fecal microbiota 
profiles we found that prior to DSS administration, both groups of recipient 
mice had similar microbial profiles, closer to control donor, based on 
abundance jaccard index (Fig 6B-C). Further analysis has confirmed that there 
were no differences between the microbiota genera of both recipient groups 
(Table S10), including genera affected by HSD such as Lactobacillus (Fig. 6D). 
When analyzed in detail, the OTUs successfully transferred from control diet-
microbiota accounted for 98.0% of the entire donor’s community, while the 
OTUs from HSD-microbiota accounted for 75.9% of the donor’s microbiota 
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community (Table 2). From the 15 most abundant OTUs of each microbiota-
type, that accounted for 99% of control diet microbiota and 95% of HSD 
microbiota, we verified that only 7 OTUs from HSD microbiota were detected in 
the recipient mice, while from control diet-microbiota 12 OTUs were present (Fig 
6E, Table 2). These results demonstrate that a significant proportion of the HSD 
OTUs did not successfully colonize the gut of recipient mice when these were 
fed control diet, suggesting that a constant exposure to high levels of NaCl in 
the diet is necessary to maintain the HSD signature microbiota profile. Taken 
together, similar colitis severity observed in the two microbiota-similar recipient 
groups supports our hypothesis that microbiota composition and function is a 
major determinant of colitis severity. 
 
 
Table 2: OTU count analysis of Microbiota Transplant Experiment 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 (see figure on page below). HSD-signature microbiota requires constant exposure to 
high salt diet for its maintenance. A: Experimental design. B: Principal coordinate analysis 
(PCoA) of abundance Jaccard index from fecal microbiota composition data. C: Summary of the 
relative microbial genera present in 99.9% of the community. Un. G (Unclassified Genus) D: 
Relative abundance of Lactobacillus genus E: Total read count of each OTU present in the 
indicated donor fecal microbiota (in green triangles). Orange dots indicate the OTUs that were 
present in recipient mice at day 5 post-colonization. The horizontal dashed line separates the 15 
most abundant OTUs from the others. F: Body weight during DSS administration. G: Macroscopic 
scores of DSS colitis at endpoint. H: Colon length at endpoint. 
  
  # of OTUs 
  
Total From 
Donor 
Successfully 
Transferred to 
Recipient 
Transferred From 15 
Most Abundant OTUs 
CTL Microbiota 103 43 (98.0%)* 12 
HSD Microbiota 134 43 (75.9%)* 7 
*Coverage of the donor microbiota community based on read counts 	
High diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production 
	 61 
 
 
  
Control 
recipient 
Control 
recipient 
Control donor 
HSD donor 
0 
All recipient mice on Control Diet 
Day post colonization 
5 10 13 
2.5% DSS 
A) B) 
C) 
E) 
F) G) H) 
Fecal sample 
collection 
OTU present in 
recipient mice 
(does not represent 
proportionality) 
Donor OTUs HSD donor 
0 25 50 75 100 125 
OTUs 
Control donor  
0 25 50 75 100 125 
100000 
10000 
1000 
100 
10 
1 
0 
# 
of
 s
eq
ue
nc
e 
re
ad
s 
OTUs 
Da
y 0
Da
y 1
Da
y 2
Da
y 3
Da
y 4
Da
y 5
Da
y 6
Da
y 7
Da
y 8
50
60
70
80
90
100
110
%
 o
f W
ei
gh
t C
ha
ng
e
Weight Loss
NSD microbiota + DSS
HSD microbiota + DSS 
0 1 2 3 4 5 6 7 
Day 
110 
100 
90 
80 
70 
60 
50 
%
 o
f i
ni
tia
l w
ei
gh
t 
2.5% DSS Colitis 
Day 0Day 1Day 2Day 3Day 4Day 5Day 6Day 7
50
60
70
80
90
100
110
%
 o
f W
ei
gh
t C
ha
ng
e
Weight Loss
NSD microbiota + DSS
HSD microbiota + DSS
Co
ntr
ol 
Mi
cro
bio
ta
HS
D 
Mi
cro
bio
ta
0
1
2
3
D
is
e
a
se
 S
c
o
re
Disease Score
HSD 
Microbiota 
Control 
Microbiota 
sc
or
e 
0 
1 
2 
3 
N.S. 
Co
ntr
ol 
Mi
cro
bio
ta
HS
D 
Mi
cro
bio
ta
0
2
4
6
8
Colon Length
C
o
lo
n
 L
e
n
g
th
 (c
m
)
HSD 
Microbiota 
Control 
Microbiota 
C
ol
on
 le
ng
th
 (c
m
) 
0 
2 
4 
6 
8 N.S. 
0.0 
0.25 
0.5 
0.75 
1.0 
B
ac
te
ria
 G
en
us
 (r
el
at
iv
e 
ab
un
da
nc
e)
 
N.S. 
HSD 
Microbiota 
Recipient 
Control 
Microbiota 
Recipient 
HS
D 
Donor 
Co
ntr
ol 
Body weight Colitis score Colon length 
Control donor 
HSD donor 
Control recipient 
HSD recipient 
0 25 50 75 100 125
0.1
1
10
100
1000
10000
100000
OTU #
NSD OTUs
Recipient
Donor
0 25 50 75 100 125
0.1
1
10
100
1000
10000
100000
OTU #
HSD OTUs
Recipient
Donor
100000 
10000 
1000 
100 
10 
1 
0 
# 
of
 s
eq
ue
nc
e 
re
ad
s 
PC2  
(1.56%) 
PC1 (98.23%) 
Abundance Jaccard 
Do
no
r C
on
tro
l
Do
no
r H
SD
Re
c C
on
tro
l
Re
c C
on
tro
l
Re
c C
on
tro
l
Re
c H
SD
Re
c H
SD
Re
c H
SD
Re
c H
SD
0.0
0.25
0.5
0.75
1.00
Taxa Summary_Genus
Porphyromonadaceae (Un. G.)
Parabacteroides
Mucispirillum
Enterococcaceae (Un. G.)
Lactobacillus
Turicibacter
Clostridiales (Un. G.)
Lachnospiraceae (Un. G.)
Lachnospiraceae (Un. G.)
Blautia
Lachnospira
Moryella
Oscillospira
Ruminococcus
Eubacterium
Enterobacter
Akkermansia
Do
no
r 
on
tro
l
Do
no
r H
SD
Re
c C
on
tro
l
Re
c C
on
tro
l
Re
c C
on
tro
l
Re
c H
SD
Re
c H
SD
Re
c H
SD
Re
c H
SD
0.00
0.25
0.50
0.75
1.00
Taxa Summary_Genus
Porphyromonadaceae (Un. G.)
Parabacteroides
Mucispirillum
Enterococc eae (Un. G.)
Lactobacillus
Turicibacter
Clostridiales (Un. G.)
Lachnospir ceae (Un. G.)
Lachnospiraceae (Un. G.)
Blautia
Lachnospira
Moryella
Oscillospira
Ruminococcus
Eubacterium
Enterobacter
Akkermansiakermansia 
t robacter 
ubacterium 
u inococcus 
Oscilospira 
ryella 
Lachnospira 
Blautia 
Lachnospiraceae (Un. G) 
chnospiraceae (Un. G) 
lostridiales (Un. G.) 
Turicibacter 
Lactobacillus 
t rococ aceae (Un. G.) 
cispirillum 
rabacteroides 
rphyromonadaceae (Un. G.) 
D) Lactobacillus 
0.0 
0.25 
0.5 
0.75 
1.0 
Co
ntr
ol 
Co
ntr
ol 
HS
D 
HS
D 
Donor 
Microbiota 
Recipient 
Microbiota 
N.S. 
R
el
at
iv
e 
ab
un
da
nc
e 
Co
ntr
ol 
Do
no
r
HS
D 
Do
no
r
Re
cip
ien
t C
on
tro
l
Re
cip
ien
t H
SD
0. 0
0.25
0.50
0.75
1.00
Genus: Lactobacillus
High diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production 
	 62 
5. Discussion 
 
 
 In addition to host genetic make-up, environmental factors such as diet 
and microbiota composition have been shown to play a crucial role in the 
development of inflammatory diseases. Here we show that high content of NaCl 
in diet modulates gut microbiota composition and function, namely decreasing 
the relative abundance of Lactobacillus spp and levels of the SCFA butyrate, 
promoting a pro-inflammatory state in the gut. We demonstrate that the gut 
microbiota is a key mediator in the exacerbation of experimental colitis by HSD, 
supported by the fact that the detrimental effect of HSD was not observed in GF 
mice. 
 To understand the impact of HSD in the modulation of gut microbiota, we 
fed mice with a diet supplemented with 4% NaCl for 4 weeks and analyzed fecal 
microbiota dynamics during and after HSD. The NaCl concentration employed 
here simulates the concentration of a typical high salt diet[18,150], which was 
shown to exacerbate the development of several immune disorders in 
mice[21,22,150]. Importantly, 4 weeks of 4% NaCl diet do not affect mouse 
blood pressure[21]. HSD altered gut microbiota composition and function, 
mainly decreasing colonic Lactobacillus spp. relative abundance and SCFA 
butyrate levels, two factors that have been implicated in the maintenance of a 
healthy gut physiology. This is in agreement with a very recently published 
study by Wilck at al showing that high salt diet alters gut microbiota, mainly by 
decreasing levels of Lactobacillus murinus, leading to induction of T helper 17 
cells[175] and that supplementation with L. murinus can abrogate the pro-
inflammatory effect of HSD. In addition to butyrate, lactic acid also appeared to 
decrease after HSD, although not significantly. Interestingly, it has been shown 
that lactic acid is used by some butyrate-producing bacteria for the production 
of high concentrations of butyric acid[176], thus it is plausible that the decrease 
observed in Lactobacillus spp. is, at least in part, indirectly responsible for the 
significant decrease of butyric acid. Several species of Lactobacillus genus have 
been shown to play a role in host’s gut mucosal immune and barrier 
function[177]. A recent study showed that Lactobacillus reuteri ameliorates 
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colitis in mice by increasing the colon mucus thickness[178]. Butyrate plays an 
essential role in gut homeostasis as it serves as the primary energy source for 
colonocytes and is important for maintaining tissue barrier function[179]. 
Moreover, it has been directly implicated in colonic Tregs’ 
differentiation[180,181], intestinal macrophage function[182], and colonic 
inflammation down regulation[183]. Furthermore, a recent study has shown that 
butyrate deficiency is directly associated with colitis[184], while small clinical 
studies have shown that butyrate treatment improves colitis[185,186].  
 We hypothesized that the changes in gut microbiota driven by HSD, in the 
absence of any additional inflammatory insult, would affect intestinal immune 
homeostasis. Our data revealed a strong impact of HSD on mucosal immunity, 
both in the colon and small intestine. Even though Na+ and Cl- ions are thought 
to be absorbed in the small intestine, HSD had a stronger impact in the colon, 
when considering the number of affected genes (35 genes in the colon and 11 
genes in the small intestine). This is in line with a recent study showing that 
HSD increased sodium luminal concentration in the colon but not in the small 
intestine[187], which may partially explain the different impact of HSD on small 
intestinal and colonic mucosal immunity. 
 Many of the altered genes were related to immune cell trafficking, cell 
viability and signal transduction elements. Rac1 gene, which was increased by 
HSD, has been associated with ulcerative colitis in many studies. Several 
polymorphisms that lead to the increase of Rac1 expression have been shown in 
patients with UC[188] and Rac1 is the target of a commonly used IBD treatment 
azathioprine[189]. Moreover, mice with a Rac1 conditional deletion in 
neutrophils and macrophages are resistant to DSS-colitis, showing reduced 
neutrophil migration and reduced levels of IL1β and KC[188]. Furthermore, the 
genes Mapk3, Map2k1, Map2k6, Atf2 and Hras1, together with Rac1, were also 
integrated by IPA to be part of the upregulated “LPS-stimulated MAPK signaling” 
as well as part of other MAPK-related canonical pathways (Table S7). This is of 
particular interest, not only because MAPK signaling pathway has been shown to 
be induced by NaCl[21,22,150], but also because microbiota-derived molecules 
such as LPS, flagellin, DNA, RNA, and others, can lead to the activation of MAPK 
signaling pathways by selectively binding to various pattern recognition 
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receptors on innate immune cells[136,190]. In agreement with previous reports, 
we found that IL-17 signaling pathway was predicted to be affected by HSD in 
both colonic and small intestine tissues[21,22,150]. 
Surprisingly, we found that HSD downregulated the expression of 
multiple chemokines, cytokines and its receptors in the colonic lamina propria. 
This was unexpected considering that previous studies have shown that NaCl 
induces macrophage chemotaxis in vitro[191], and that macrophages infiltrate 
the skin of rodents fed with HSD in response to the storage of Na+ in this organ, 
a mechanism important to maintain interstitial electrolyte and volume 
homeostasis[192]. However, several other studies have shown downregulation 
of the expression of chemokine receptors in neutrophils and other granulocytes, 
upon TLR engagement in a p38-MAPK signaling dependent manner, with cells 
remaining partially functionally competent; a potential mechanism regulating 
cell positioning and activation[193,194]. Considering that HSD induced changes 
in colonic microbiota and upregulation of MAPK signaling pathways in the colon, 
it is conceivable that the observed downregulation of chemokine receptors and 
other molecules is a result of mucosal granulocytes TLR engagement. 
Downregulation of cytokines and chemokines could compromise the colonic 
immune barrier, and promote a pro-inflammatory response or impaired 
resolution of inflammation after the intestinal injury induced by DSS and DNBS.  
 To investigate the effect of HSD induced alterations in mucosal immune 
function and gut microbiota, we used two different models of experimental 
colitis. We confirmed that HSD exacerbates colitis in mice [150] and showed 
enhanced colonic barrier disruption after DSS in mice fed HSD. In fact, Ocln and 
ZO-1, two components of the tight junction (TJ) structure, were significantly 
downregulated, as well as Muc2, a protein secreted by goblet cells (GC) and 
essential for the structure of the mucus layer in the intestine, and Tff3, also 
mostly expressed by GC, with a key role in mucus layer stability and mucosal 
repair [195]. On other hand, Mmp9 and Cnlp were upregulated in HSD mice 
after DSS-colitis. Even though Cnlp has been proposed to have a protective role 
[196], the level of this peptide has been shown to be elevated in DSS colitis and 
patients with Ulcerative colitis [197,198]. Mmp9 is markedly elevated in 
intestinal tissues of IBD patients and it has been proposed to be a biomarker of 
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disease activity [199–201]. Mmp9 is also elevated in DSS colitis and has been 
shown to contribute to the severity of colitis by increasing intestinal epithelial TJ 
permeability [201]. Cnlp and Mmp9 are highly expressed by active neutrophils, 
therefore their upregulation could also reflect the increased infiltration of these 
cells in the inflamed colonic tissue of HSD mice after DSS administration. We 
reproduced the colitis results in a different mouse strain, and showed that HSD 
leads to a similar exacerbation of DSS colitis in NIH Swiss as in C57BL/6 mice, 
suggesting that HSD-mediated exacerbation of experimental colitis is 
independent of mouse genotype. Further supporting our results, several studies 
have recently reported increased severity of colonic inflammation not only in 
models of chemically induced colitis[150,202], but also in IL-10 KO mice, which 
spontaneously develop colitis, and in Salmonella typhimurium infected mice, 
while on HSD[187]. 
 In order to test whether gut microbiota plays a role in the HSD-dependent 
exacerbation of gut injury, we induced DSS colitis in GF mice. While DDS 
induced colitis in both groups of germ-free mice, there was no worsening of the 
colonic inflammation in mice fed a HSD. This suggests that the increased 
susceptibility to colitis induced by a HSD is critically dependent on the presence 
of the microbiota. In subsequent experiments, we found no difference in colitis 
severity when transferring gut microbiota from SPF mice on a HSD into germ-
free recipients. Although seemingly counterintuitive, the results are in 
accordance with our previous data as we found that at the beginning of DSS 
administration (five days post-colonization) the microbiota of all recipient mice 
had converged to a similar profile, regardless of the donor microbiota. This is in 
sharp contrast with our SPF mice experiment, where we observed a marked 
dysbiosis prior to commencing DSS and subsequently worse colitis in mice 
previously on high salt diet. In our transfer experiment, most of the abundant 
OTUs from the control diet donor were transferred to the recipient mice while 
only a minority of abundant HSD donor OTUs were detected in the recipient 
mice. These differences in microbiota profiles could be partially attributed to 
technical issues, including freezing and thawing, and exposure to oxygen, as we 
did not use fresh cecal content samples for colonizations.  However, we believe 
that the major factor accounting for this difference was the fact that recipient 
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mice were given control diet, which did not allow establishment of HSD 
microbiota profiles. Thus, the microbiota transfer experiment supports the 
notion that HSD-induced dysbiosis, and its altered metabolic activity, is a major 
determinant of the sensitivity to inflammatory insult in this model and that a 
constant exposure to HSD is necessary to maintain the “pro-inflammatory” 
microbiota profile. 
 Even though it has been previously shown that NaCl can directly affect 
immune cells in vitro, we hypothesize that these direct effects do not play a 
major role in our in vivo model.  Taking into consideration that i) dysbiosis, 
including the depletion of Lactobacillus and butyrate, is known to affect 
mucosal immune homeostasis, and that ii) the mucosal milieu in the colon, 
which harbors the highest microbial density along the GI tract, was more 
affected by HSD than small intestine, and that iii) multiple immune pathways 
affected by HSD are strongly modulated by microbial products, we hypothesize 
that changes in the immune system are a consequence of the disruption of the 
gut microbiota by HSD. This notion is further supported by the lack of changes 
in colonic mucosal immune milieu in germ-free mice on HSD (Table S9).  
 Taken together, this study provides an example of how environmental 
factors, such as diet, play a key role in shaping gut microbial communities that 
influence host physiology and predisposition to disease.  
 
 
6. Conclusions 
 
 We have demonstrated that consumption of a diet with high salt content 
results in alteration of gut microbiota composition and function that may be 
pro-inflammatory by virtue of the loss of Lactobacillus spp. and reduced 
production of the protective SCFA butyrate. Our findings indicate that the 
maintenance of the pro-inflammatory microbiota is dependent on a continued 
high salt intake, and is associated with changes in gut immune homeostasis, 
predisposing mice to the development of a more severe form of experimental 
colitis. Our study suggests that high concentrations of dietary salt, similar to 
those found in the Western Diet, contribute to the increased prevalence of 
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chronic inflammatory disorders through microbiota dependent mechanisms. 
This finding has implications for the management of patients with IBD and other 
inflammatory disorders and should be further investigated, as it provides an 
easy candidate for dietary therapeutic interventions. 
 
 
7. Supplementary Figures 
 
Supplementary Figure 1. HSD affects richness and diversity of fecal microbiota. Observed 
species and Chao1 diversity index of fecal microbiota at the indicated time points after 
introduction of HSD. 
 
Supplementary Figure 2. Weighted Unifrac distance metrics of gut microbiota of mice fed 
with HSD. PCoA plot of weighted unifrac metric of fecal microbiota composition over time 
exposed to HSD. 
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Supplementary Figure 3. Gut microbiota is stable in mice on control diet during week 8-12 A: 
Summary of the relative abundance of microbial genera present in 99.9% of the community before 
and after 4 weeks on control diet. (Un. G: Unclassified Genus) B: Summary of the t-test statistical 
analysis of microbiota genera before and after 4 weeks on control diet. Highlighted in red are the 
taxa that were shown to correlate with HSD. C: PCoA plots of abundance Jaccard index (left 
panels) and unweighted unifrac metric (right panels) of fecal microbiota composition from mice 
on control and high salt diet, at the beginning of the experiment (Baseline) and 4 Weeks of diet. 
Anosim statistical analysis of respective distance metrics.  
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Supplementary Figure 4. HSD modulates immune expression in small intestine lamina 
propria. A: Volcano plot of gene expression in small intestine lamina propria total cell extract of 
mice receiving HSD or control diet for 4 weeks, n=9 mice/group. Blue dots: genes with p < 0.05, 
fold change > 2. B: Heatmap of immune genes that changed with HSD (p<0.05). The heatmap was 
generated based on group average, using Euclidean distance metric. 
 
 
 
 
 
Supplementary Figure 5. HSD increases RORgt+ IL17+ Cells in mLN but it doesn’t affect FoxP3 
cells. Total cell extract of mesenteric lymph nodes (mLNs), small intestine lamina propria (SI LP) 
and colonic lamina propria (Col LP) was performed on mice fed HSD for 4 weeks (and control 
diet). Cells were analyzed with flow cytometry. Indicated % are from viable cells gated on TCRb+ 
CD4+. This is a representative experiment of 3 other different independent experiments. Values 
are presented as means ± SEM; n = 6-9 mice/group. * (p<0.05).  
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Supplementary Figure 6. HSD increases susceptibility to DSS colitis in NIH Swiss mice. Mice, 
previously fed HSD or control diet, were exposed to 3.5% DSS in drinking water during 5 days. DSS 
(Control diet, DSS in water), HSD+DSS (High salt diet, DSS in water). A: Body weight changes 
during DSS treatment B: Clinical assessment of DSS colitis at endpoint (Day 7). C: Colon length at 
endpoint. D: Histology score of colonic sections. Values are presented as means ± SEM; n = 5 
mice/group. * (p<0.05) ** (p<0.01). 			 	
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8. Supplementary Tables 	
Table S1 	 										
Table S2 	 	 	
Table S1 - Fecal microbiota genera that significantly correlates with HSD
Taxonomy (Genus) Spearman r p-value q (FDR)
Lactobacillus -0.703 1.39E-04 0.003
Lachnospiraceae (Un. Genus) 0.614 0.002 0.017
Clostridiales (Un. Genus) -0.605 0.002 0.017
Oscillospira 0.548 0.007 0.042
Table S2 - Fecal microbiota OTU that significantly correlates with HSD
Taxonomy (OTUs) Spearman r p-value q (FDR)
OTU3: g__Lactobacillus -0.707 1.22E-04 0.005
OTU9: o__Clostridiales -0.684 2.62E-04 0.005
OTU25: f__Lachnospiraceae 0.609 0.002 0.027
OTU10: g__Oscillospira 0.482 0.022 0.214
OTU24: f__Lachnospiraceae 0.454 0.033 0.214
OTU16: f__Lachnospiraceae -0.454 0.033 0.214
OTU2: f__Lachnospiraceae 0.427 0.047 0.260
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Table S3 	
	 	
Table S3 - List of the genes that are significantly altered by HSD in colonic lamina propria
Gene Code Gene Name Accession # log2(ratio) P value Type
Ccl3 C-C motif Chemokine Ligand 3 NM_007482.3 -1.42 0.0091 Chemokine
Ccl4 C-C motif Chemokine Ligand 4 NM_144938.2 -1.45 0.0182 Chemokine
Cxcl10 C-X-C motif Chemokine Ligand 10 NM_009777.2 -0.9 0.017 Chemokine
Cxcl2 C-X-C motif Chemokine Ligand 2 NM_016960.1 -2.07 0.039 Chemokine
Ccr7 C-C motif Chemokine Receptor 7 NM_013653.1 -1.9 0.047 Chemokine Receptor
Cxcr4 C-X-C motif Chemokine Receptor 4 XM_356827.6 -1.5 0.0259 Chemokine Receptor
Csf2 Colony Stimulating Factor NM_007465.2 -1.73 0.0157 Cytokine
Ifi27l2a Interferon Alpha Inducible Protein 27 Like 2 NM_009744.3 -1.13 0.0101 Cytokine
Il1b Interleukin 1 Beta NM_013654.2 -1.39 0.0476 Cytokine
Il7 Interleukin 7 NM_009662.2 0.47 0.0033 Cytokine
Tnfsf14 Tumor Necrosis Factor Superfamily Member 14 NM_023143.3 -1.39 0.0181 Cytokine
Il1rap Interleukin-1 Receptor Accessory Protein NM_007440.4 0.19 0.0005 Cytokine receptor
Cysltr2 Cysteinyl Leukotriene Receptor 2 NM_133882.2 -1.11 0.0287 Leukotrienes Receptor
Ltb4r1 Leukotriene B4 Receptor 1 NM_019577.4 -0.78 0.043 Leukotrienes Receptor
Atf2 Activating Transcription Factor 2 NM_146148.1 0.27 0.0265 Transcription Factor
Cebpb CCAAT/Enhancer Binding Protein Beta NM_007572.2 -0.87 0.0165 Transcription Factor
Irf5 Interferon Regulatory Factor 5 NM_011888.2 -0.71 0.0343 Transcription Factor
Mef2c_Mm Myocyte-specific Enhancer Factor 2C NM_009778.2 -0.67 0.021 Transcription Factor
Myc V-Myc Avian Myelocytomatosis Viral Oncogene Homolog NM_011332.2 -0.39 0.0316 Transcription Factor
Keap1 Kelch-like ECH-associated Protein 1 NM_013652.1 0.35 0.045 Regulatory Element
Ptgs2 Prostaglandin-endoperoxide Sunthase 2 (aka COX-2) NM_011330.3 -1.67 0.0307 Signal Transduction Enzyme
Map2k1 Mitogen-Activated Protein Kinase Kinase 1 NM_009704.3 0.59 0.0061 Signal Transduction Kinsases
Map2k6 Mitogen-Activated Protein Kinase Kinase 6 NM_016704.2 0.41 0.0219 Signal Transduction Kinsases
Mapk3 Mitogen-Activated Protein Kinase 3 NM_009743.4 0.52 0.01 Signal Transduction Kinsases
Ptger3 Prostaglandin E Receptor 3 NM_009779.2 1.35 0.021 Signal Transduction Receptor
Gnb1 G-Protein Subunit Beta 1 NM_009660.3 0.25 0.0015 Signaling Transduction
H2-Eb1 Histocompatibility 2, class II antigen E Beta NM_011124.4 -0.77 0.0394 Signaling Transduction
Hras1 GTPase Hras (aka Transforming Protein p21) NM_013484.2 -2.41 0.0192 Signaling Transduction
Rac1 Ras-related C3 botulinum toxin substrate 1 NM_007425.2 0.41 0.0001 Signaling Transduction
Tyrobp TYRO Protein Tyrosine Kinase Binding Protein NM_013485.1 -1.39 0.03 Signaling Transduction
Alox15 Arachidonate 15-lipoxygenase NM_001025093.
1
-3.27 0.0098 Lipid Oxidation Enzyme
Alox5 Arachidonate 5-lipoxygenase NM_009137.2 -1.84 0.0411 Lipid Oxidation Enzyme
Arg1 Arginase1 NM_011413.2 -0.6 0.0216 Enzyme
Itgb2 Integrin Subunit Beta 2 (aka CD18) NM_011337.1 -0.77 0.0444 Integrin
Cfb Complement Factor B NM_011333.3 0.41 0.0346 Complement Factor
*From IPA analysis
Cytokines, Chemokine and Receptors
Transcription Factors and Regulators
Signal Transduction Elements 
Other
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Table S4 
		
Table S5 	
	
Funtion Or Disease Genes involved p-value Activation
Colon
adhesion of immune cells ALOX15,CCL3L3,CCL4,CCR7,CSF2,CXCL10,CXCL3,CXCR4,HRAS,IL1B,IL7,ITGB2,LTB4R,MAP2K1,PTGS2,RAC1 3.18E-18 -2.268
cellular homeostasis ARG1,CCL3L3,CCL4,CCR7,CSF2,CXCL10,CXCL3,CXCR4,HRAS,IL1B,IL7,IRF5,ITGB2,LTB4R,MAP2K1,MAPK3,MEF2C,MYC,PTGS2,
RAC1,TYROBP
8.01E-17 -1.409
leukocyte migration ALOX15,ALOX5,CCL3L3,CCL4,CCR7,CSF2,CXCL10,CXCL3,CXCR4,HRAS,IL1B,IL7,IRF5,ITGB2,LTB4R,MYC,PTGS2,RAC1,TNFSF14,
TYROBP
9.04E-17 -3.291
cell movement of leukocytes ALOX5,CCL3L3,CCL4,CCR7,CSF2,CXCL10,CXCL3,CXCR4,HRAS,IL1B,IL7,ITGB2,LTB4R,MYC,PTGS2,RAC1,TNFSF14,TYROBP 1.64E-15 -3.017
inflammatory response ALOX5,CCL3L3,CCL4,CCR7,CEBPB,CSF2,CXCL10,CXCL3,CXCR4,IL1B,ITGB2,LTB4R,PTGS2,RAC1,TNFSF14,TYROBP 4.47E-15 -3.311
Inflammatory Response ALOX5,CCL3L3,CCL4,CCR7,CEBPB,CSF2,CXCL10,CXCL3,CXCR4,IL1B,ITGB2,LTB4R,PTGS2,RAC1,TNFSF14,TYROBP 4.47E-15 -3.3
Leukocyte Migration ALOX15,ALOX5,CCL3L3,CCL4,CCR7,CSF2,CXCL10,CXCL3,CXCR4,HRAS,IL1B,IL7,IRF5,ITGB2,LTB4R,MYC,PTGS2,RAC1,TNFSF14,
TYROBP
9.04E-17 -3.29
Cell Movement of myeloid Cells ALOX5,CCL3L3,CCL4,CCR7,CSF2,CXCL10,CXCL3,CXCR4,HRAS,IL1B,ITGB2,LTB4R,PTGS2,RAC1,TYROBP 2.69E-14 -3.26
Migration of Cells ALOX15,ALOX5,CCL3L3,CCL4,CCR7,CSF2,CXCL10,CXCL3,CXCR4,HRAS,IL1B,IL7,IRF5,ITGB2,LTB4R,MAP2K1,MYC,PTGS2,RAC1,
TNFSF14,TYROBP
8.76E-15 -3.2
Cell Movement of phagocytes ALOX5,CCL3L3,CCL4,CCR7,CSF2,CXCL10,CXCL3,CXCR4,HRAS,IL1B,ITGB2,LTB4R,PTGS2,RAC1,TYROBP 3.99E-14 -3.01
Cell Viability of lymphocytes IL7,MAP2K1,MAPK3,MYC 5.98E-04 1.925
Cell Viability of mononuclear 
leukocytes
CSF2,IL7,MAP2K1,MAPK3,MYC 5.01E-05 1.478
Maturation of Lymphocytes CSF2,IL7,MAPK3,MYC,PTGS2,TYROBP 9.96E-08 1.109
Quantity of Lymphoid tissue ARG1,CCR7,CXCR4,IL7,ITGB2,MAPK3,RAC1,TYROBP 1.28E-06 1.06
Cell Cycle Progression CSF2,HRAS,IL1B,IL7,MAP2K1,MAP2K6,MYC,PTGS2 9.25E-05 0.599
*From IPA analysis
Top 5 
(Lowest 
P-values)
Bottom 5 
z-score
Top 5 z-
score
Table S5 - Most significant functions or diseases altered by HSD in colonic lamina propria
Table S4 - Most significant canonical pathways altered by HSD in colonic lamina propria
Canonical Pathways Genes involved p-value Ratio z-score
Colon
Role of Macrophages, Fibroblasts and Endothelial Cells in 
Rheumatoid Arthritis
MAP2K6,MYC,MAPK3,RAC1,HRAS,IL1B,CEBPB,CSF2,MAP2K1,IL1RAP,IL7,ATF2 1.07E-12 4.03E-02 NaN
Role of IL-17F in Allergic Inflammatory Airway Diseases CXCL10,CCL4,MAPK3,IL1B,CSF2,MAP2K1,ATF2 3.22E-12 1.71E-01 0
IL-17 Signaling CXCL10,MAP2K6,MAPK3,HRAS,CEBPB,PTGS2,MAP2K1,ATF2 1.05E-11 9.52E-02 NaN
Communication between Innate and Adaptive Immune Cells CXCL10,CCL4,CCL3L3,IL1B,CSF2,HLA-DRB5,CCR7 6.07E-10 8.33E-02 NaN
Acute Phase Response Signaling MAP2K6,MAPK3,CFB,HRAS,IL1B,CEBPB,MAP2K1,IL1RAP 1.34E-09 5.23E-02 0.707
Eicosanoid Signaling ALOX15,LTB4R,PTGER3,PTGS2,ALOX5,CYSLTR2 4.57E-09 9.68E-02 NaN
IL-6 Signaling MAP2K6,MAPK3,HRAS,IL1B,CEBPB,MAP2K1,IL1RAP 8.45E-09 5.74E-02 0.378
LPS-stimulated MAPK Signaling MAP2K6,MAPK3,RAC1,HRAS,MAP2K1,ATF2 3.36E-08 6.98E-02 1.633
p38 MAPK Signaling MAP2K6,MYC,IL1B,MEF2C,IL1RAP,ATF2 1.48E-07 5.45E-02 0
*From IPA analysis
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Table S6 																									
Table S7 		
				 	
Table S7 - Most significant canonical pathways altered by HSD in small intestine lamina propria
Canonical Pathways Genes involved p-value Ratio z-score
Small Intestine
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses MAP2K4,IL12A,TLR1,TLR9,IL17A 9.01E-09 3.79E-02 NaN
Toll-like Receptor Signaling MAP2K4,IL12A,TLR1,TLR9 8.59E-08 5.56E-02 NaN
IL-17 Signaling MAP2K4,TLR9,IL17A 1.76E-05 3.57E-02 NaN
Communication between Innate and Adaptive Immune Cells IL12A,TLR1,TLR9 1.76E-05 3.57E-02 NaN
p38 MAPK Signaling MAP2K4,MEF2C,MEF2B 3.95E-05 2.73E-02 NaN
*From IPA analysis
Gene Code Gene Name Accession # log2(ratio) P value Type
Il12a Interleukin 12A NM_008351.1 -4.56 0.0141 Cytokine
Il17a Interleukin 17A NM_010552.3 2.1 0.0381 Cytokine
Cxcr4 C-X-C motif Chemokine Receptor 4 NM_009911.3 -1.3 0.0464 Chemokine receptor
Ltb4r2 Leukotriene B4 Receptor 2 NM_020490.2 1.35 0.0139 Leukotrienes Receptor
Mafk V-Maf Avian Musculoaponeurotic Fibrosarcoma NM_010757.2 -0.42 0.0133 Transcription Factor
Mef2b Myocyte-specific Enhancer Factor 2B NM_001045484.1 -1.84 0.0201 Transcription Factor
Mef2c_Mm Myocyte-specific Enhancer Factor 2C NM_025282.2 -0.88 0.0316 Transcription Factor
Map2k4 Mitogen-Activated Protein Kinase Kinase 4 NM_009157.4 -0.15 0.0123 Signal Transduction Kinsases
Tlr1 Toll-Like Receptor 1 NM_030682.1 -0.7 0.024 Receptor
Tlr9 Toll-Like Receptor 9 NM_031178.2 -0.82 0.033 Receptor
Defa-rs1 Alpha-Defensin-Related Sequence 1 NM_007844.2 0.5 0.0371 Defensin
*From IPA analysis
Cytokines, Chemokine and Receptors
Transcription Factors and Regulators
Signal Transduction Elements 
Innate Immunity System
Table S6- List of the genes that are significantly altered by HSD in small intestine lamina propria
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Table S8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Gene Name Gene Function DSS* DSS* DSS* Control* Control* Control* log2ratio p-value
GABAB Neuro 616.07 735.68 632.93 189.68 172.53 168.23 1.9 0.0001
Tjp1 Barrier 2192.85 2423.08 2210.85 1410.66 1233.45 1305.33 0.79 0.0005
Cdh1 Barrier 18558.07 17560.81 16639.28 11999.26 12128.77 10918.29 0.59 0.0009
Mapk1 Immune 4223.89 4414.01 4148.45 3550.86 3416.6 3458.43 0.29 0.0016
Nfkb1 Immune 1645.58 1844.32 1874.55 1240.21 1098.16 1217.55 0.59 0.0019
NFAT Immune 1502.39 1691.27 1592.82 1127.83 1105.94 1061.49 0.54 0.0023
Muc2 Barrier 57291.14 61718.74 55687.45 15352.86 10675.6 12250.46 2.21 0.0027
SEMAPHORIN Neuro 198.83 234.09 189.73 86.14 83.96 112.14 1.15 0.0032
Tollip Immune 1157.57 1243.7 1072.79 872.77 888.89 801.4 0.44 0.0059
GDNF Neuro 63.05 119.63 97.31 31.85 16.8 21.11 2.01 0.0064
Tff3 Barrier 93229.47 109376.23 89628.82 61487.63 60132.8 47410.46 0.79 0.0076
P75 Neuro 156.04 154.35 198.64 96.24 80.07 107.27 0.84 0.0079
NOS Neuro 266.32 375.56 266.57 163.16 154.04 108.89 1.09 0.0115
Il23r Immune 52.35 43.74 23.81 6.59 2.2 8.11 2.95 0.019
Tlr4 Immune 867.07 964.61 940.27 446 537.53 621.77 0.8 0.0202
F2rl1 Immune 2594.45 2590.28 2353.39 2218.76 2074.39 1941.75 0.27 0.0204
Tlr5 Immune 73.74 83.61 101.76 52.05 59.63 40.62 0.77 0.0229
Hif1a Immune 2278.43 2987.69 2397.93 4239 3347.49 3746.16 -0.57 0.023
CHAT Neuro 46.59 74.61 31.61 17.96 6.09 5.67 2.49 0.0236
Rae1 Barrier 823.45 926.03 874.57 757.87 753.6 671.35 0.27 0.0248
Ocln Barrier 3872.49 3750.37 3223.08 2606.39 2924.1 2203.47 0.49 0.0321
CALRET Neuro 18949.8 16364.71 20667.03 11789.66 14783 14612.45 0.44 0.0376
CD11C Immune 140.4 118.34 125.15 67.2 44.05 76.38 1.07 0.0377
Il22ra2 Immune 265.49 249.52 315.57 434.63 350.65 519.36 -0.64 0.0384
SOX10 Neuro 53.17 69.47 86.17 24.27 44.05 19.49 1.31 0.0441
* Normalized transcript counts
Table S8 - List of genes that are statistically altered by DSS in Germ-Free mice
Gene expression was acquired using Nanostring technology, from a costumized gene panel
High diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production 
	 76 
Table S9 
 
 
 
 
  
Gene Name Accession # %CV** Control Diet* Control Diet* Control Diet* HSD* HSD* HSD* log2ratio p-value
NFAT NM_010901.2 5.04 1204.52 1181.14 1133.67 1224.86 1299.2 1278.44 0.11 0.0366
Hif1a NM_010431.2 22.36 4527.23 3575.11 4000.88 3097.03 2266.78 3356.97 -0.49 0.0874
Mapk1 NM_011949.3 4.56 3792.3 3648.91 3693.58 3373.96 3418.93 3649.66 -0.09 0.0998
Tff3 NM_011575.2 16 65668.45 64221.5 50634.1 49948.18 51113.29 43974.82 -0.31 0.1062
I-FABP NM_007980.2 30.2 1342.06 1255.99 1019.95 2324.59 1504.1 1427.85 0.51 0.1339
Cldn2 NM_016675.3 7.69 1854.49 1969.08 1868.05 1578.47 1713.06 1863.82 -0.15 0.159
CALRET NM_007591.3 11.63 12591.29 15788.17 15606.02 15721.58 17905.79 17265.02 0.22 0.1688
Muc2 NM_023566.2 19.3 16396.77 11401.49 13083.42 16955.2 14441.21 19648.53 0.33 0.1804
Tollip NM_023764.3 10.42 932.12 949.33 855.89 868.96 838.99 698.17 -0.19 0.1805
Tlr5 NM_016928.2 18.4 55.59 63.68 43.38 49.6 40.53 42.17 -0.29 0.2171
P75 NM_033217.3 13.79 102.79 85.51 114.56 94.23 80.37 85.15 -0.21 0.2214
T-bet NM_019507.1 90.07 5.69 1.04 2.58 1.14 1 1.02 -1.24 0.2229
GFAP NM_001131020.1 28.26 82.56 61.6 45.98 45.03 54.35 40.12 -0.42 0.226
Cldn1 NM_016674.3 13.83 114.92 105.26 114.56 78.21 95.82 111.76 -0.24 0.2416
SOX10 NM_011437.1 29.76 25.92 47.05 20.81 45.03 38.9 44.21 0.54 0.2645
Cdh1 NM_009864.2 6.01 12815.14 12953.46 11660.67 11229.98 12488.97 11543.17 -0.09 0.2665
GATA-3 NM_008091.3 25.39 32.66 15.86 32.09 37.02 35.65 37.05 0.52 0.2697
GABAB NM_019439.3 9.52 202.58 184.26 179.67 224.69 182.82 215.12 0.13 0.2893
Cnlp NM_009921.2 67.37 9.74 1.31 3.45 11.84 3.94 12.49 1.24 0.2908
5HT NM_010484.2 18.19 271.35 250.79 236.09 207.52 263.32 158.83 -0.3 0.293
VIP NM_011702.2 24.32 729.84 897.36 507.79 584.02 567.41 504.75 -0.33 0.3007
NPY NM_023456.2 99.59 1.35 5.47 1 1 1 1.02 -0.95 0.3356
CD11C NM_021334.2 32.58 71.77 47.05 81.57 82.79 121.03 60.59 0.38 0.3703
NOS NM_008712.2 17.69 174.26 164.51 116.3 205.24 163.31 154.74 0.21 0.3971
TGR5 NM_174985.1 106.61 5.69 1.04 1 1 1 1.02 -0.84 0.415
Myd88 NM_010851.2 16.97 437.22 504.43 610.22 477.59 682.06 604.02 0.18 0.4244
CALB NM_009788.4 104.92 5.69 1.04 1 1.14 1 1 -0.79 0.4404
NR2B NM_008171.3 5.43 1 1.04 1 1.14 1 1.02 0.06 0.4445
CCR6 NM_001190333.1 69.96 70.42 25.22 131.92 56.47 220.22 89.24 0.75 0.4559
HMGB1 NM_010439.3 7.16 1478.26 1496.11 1251.72 1325.56 1367.5 1303 -0.08 0.4572
Gpr44 NM_009962.2 58.53 3 1.04 1 1.14 1 1.02 -0.47 0.4606
CD11b NM_001082960.1 35.93 25.92 32.5 69.42 40.45 60.86 52.4 0.38 0.4792
Rae1 NM_175112.5 6.4 809.4 804.84 717 707.61 725.97 800.51 -0.06 0.4798
F2rl1 NM_007974.4 7.77 2369.62 2215.44 2073.78 2242.19 2206.61 1880.2 -0.08 0.4898
Nfkb1 NM_008689.2 8.8 1324.53 1172.83 1300.33 1182.52 1365.87 1475.95 0.08 0.5125
Casp8 NM_009812.2 13.47 580.16 612.54 700.5 476.45 590.18 688.96 -0.12 0.5382
Il23r NM_144548.1 43.88 7.04 2.35 8.66 8.41 10.45 4.3 0.47 0.547
Tlr4 NM_021297.2 26.33 476.32 574.07 664.04 452.42 899.15 697.14 0.21 0.5536
SUBP XM_006505028.1 27.15 487.11 451.41 276.02 376.89 426.75 230.47 -0.24 0.5603
BDNF NM_007540.4 88.97 1.65 1.04 1 4.97 1 1.02 0.52 0.571
Reg3g NM_011260.1 54.64 40.76 8.59 41.64 22.14 63.3 29.89 0.51 0.6009
CGRP NM_007587.2 12.48 1.35 1.04 1 1.14 1 1.02 -0.09 0.6038
Defcr1 NM_010031.2 12.48 1.35 1.04 1 1.14 1 1.02 -0.09 0.6038
GABAA NM_010252.4 12.48 1.35 1.04 1 1.14 1 1.02 -0.09 0.6038
Il17a NM_010552.3 12.48 1.35 1.04 1 1.14 1 1.02 -0.09 0.6038
PGP9.5 NM_011670.2 12.48 1.35 1.04 1 1.14 1 1.02 -0.09 0.6038
TAAR1 NM_053205.1 12.48 1.35 1.04 1 1.14 1 1.02 -0.09 0.6038
SEMAPHORIN NM_011352.2 17.37 92 89.67 119.77 96.52 134.85 96.41 0.11 0.6128
S100BETA NM_009115.3 49.2 11.09 8.59 9.53 17.56 11.26 2.25 -0.34 0.7414
NR2D NM_008172.2 18.51 42.1 36.65 26.89 41.59 29.15 41.14 0.09 0.7462
Il22ra2 NM_178258.5 40.16 464.19 374.49 554.67 312.81 899.97 484.28 0.17 0.7512
CCR2 NM_009915.2 30.86 175.61 206.09 306.4 152.6 308.04 181.35 -0.13 0.7612
CXCR3 NM_009910.2 26.02 42.1 52.25 42.51 40.45 63.3 28.86 -0.11 0.7684
MMP9 NM_013599.2 33 92 72 36.44 73.64 51.91 47.28 -0.14 0.7757
Pparg NM_011146.1 25.97 25.92 16.9 18.21 24.43 12.07 21.7 -0.11 0.7901
CHAT NM_009891.2 73.29 19.18 6.51 6.05 23.28 1 14.53 -0.39 0.8176
trpv1 NM_001001445.1 40.53 11.09 7.55 6.05 11.84 3.13 10.44 -0.13 0.8585
Cxcr4 NM_009911.3 41.77 449.35 222.72 328.97 233.85 604.82 283.69 0.1 0.8623
Mylk3 NM_175441.5 123.04 12.44 1.04 1 1.14 6.38 1.02 -0.26 0.8677
TAAR4 NM_001008499.1 69.65 7.04 2.35 5.18 3.83 1.5 11.46 -0.13 0.9037
Lyz1 NM_013590.3 45.08 7008.48 7605.24 11796.09 5960.21 17006.51 7054.53 0.06 0.9136
Tlr2 NM_011905.2 35.18 100.09 84.47 162.3 81.65 178.76 102.55 0.04 0.9289
Tjp1 NM_009386.1 4.42 1506.58 1317.32 1394.09 1414.82 1381.32 1429.9 0 0.9409
C3 NM_009778.2 41.53 5196.09 2381.76 3592.89 3200.02 6301.34 2355.06 0.03 0.9555
Nod2 NM_145857.2 66.67 7.04 6.51 26.89 6.12 10.45 17.61 -0.04 0.9591
GDNF NM_010275.2 38.74 34.01 17.94 22.55 41.59 17.76 19.65 0.03 0.9593
Ocln NM_008756.2 17.75 2783.61 3122.92 2353.3 2423 3586.42 2406.23 0.01 0.9652
Cd86 NM_019388.3 38.99 62.33 33.54 63.35 35.87 89.32 43.19 0.02 0.9685
* Normalized transcripts counts
** Coefficient of variation percantage
Table S9 - Effect of HSD in Germ Free mice colonic gene expression
Gene expression was acquired using Nanostring technology, from a customized gene panel
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Table S10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TAXONOMY: GENERA Test-Statistic p-Value q (FDR)
Moryella -3.738 0.013 0.229
Parabacteroides 2.577 0.050 0.419
Enterobacter -2.255 0.074 0.419
Akkermansia -1.768 0.137 0.525
Mucispirillum 1.630 0.164 0.525
Turicibacter 1.535 0.185 0.525
Lachnospira -1.387 0.224 0.544
Oscillospira -1.198 0.285 0.545
Ruminococcus -1.187 0.289 0.545
Lachnospiraceae (Unclassified Genus) -1.098 0.322 0.548
Lactobacillus 0.794 0.463 0.655
Eubacterium -0.772 0.475 0.655
Clostridiales (Unclassified Genus) 0.725 0.501 0.655
Blautia -0.173 0.869 1.000
Porphyromonadaceae (Unclassified Genus) 0.094 0.929 1.000
Enterococcaceae (Unclassified Genus) -0.064 0.952 1.000
Table S10 - Fecal microbiota genera comparison between recipient mice groups
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9. Supplementary methods 
 
Macroscopic evaluation of DSS colitis in mice 
 
Presence of pellets in proximal colon 
  
yes 0 
no 0.5 
Presence of pellets in distal colon 
  
yes 0 
no 0.5 
Pellet consistency  
  
  
normal 0 
soft 0.5 
diarrhea 1 
Blood in anus 
  
yes 0.5 
no 0 
Blood in cecum 
  
yes 0.5 
no 0 
Blood in colon 
  
yes 0.5 
no 0 
Bloody stool 
  
yes 0.5 
no 0 
Pale and rigid distal colon  
  
yes 0.5 
no 0 
 
 
Macroscopic evaluation of DNBS colitis in mice 
 
Ulcer # of ulcers and size (cm) 
Diarrhea (0-3) 
Adhesions (0-3) 
Thickness (0-3) 
Hyperemia (0-3) 
Inflammation (0-3) 
 
Ulcer scoring: 
2 points for each ulcer < than 0.5cm 
3 points for each ulcer 0.5cm < x < 1cm 
4 points for each ulcer => than 1cm 
 
Histology scores 
 
Loss of architecture (0-3) 
Cellular infiltrate (0-3) 
Goblet cell depletion (0-1) 
Ulcers (0-1) 
Edema (0-1) 
Muscle thickening (0-2) 
Crypt abscess (0-1) 
 
 
Primer’s list 
All primers used for Q-PCR analyses were QuantiTech Primer Assay primers (Qiagen). Mm_Csf2 (Ref: 
249900), Mm_Alox15_1 (Ref: 249900), Mm_Atf2_1 (Ref: 249900), Mm_Rac1_1 (Ref: 249900). As 
reference gene we used the TATA-box biding protein (Tbp) as previously described[203]. 
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Nanostring custom genes panel 
 
Official Symbol Name Accession # 
5HT Serotonin NM_010484.2 
BDNF Brain-derived neurotrophic factor NM_007540.4 
C3 Complement component 3 NM_009778.2 
CALB Calbindin 1 NM_009788.4 
CALRET Calreticulin NM_007591.3 
Casp8  Caspase 8 NM_009812.2 
CCR2 C-C chemokine receptor type 2 NM_009915.2 
CCR6 C-C chemokine receptor type 6 NM_001190333.1 
CD11b Integrin subunit alpha M NM_001082960.1 
CD11C Integrin subunit alpha X NM_021334.2 
Cd86 CD86 NM_019388.3 
Cdh1 E-cadherin NM_009864.2 
CGRP Calcitonin gene-related peptide NM_007587.2 
CHAT Choline acetyltransferase NM_009891.2 
Cldn1 Claudin 1 NM_016674.3 
Cldn2 Claudin 2 NM_016675.3 
Cnlp Cathelin-related antimicrobial peptide (CRAMP) NM_009921.2 
Cxcr3 C-X-C motif chemokine receptor 3 NM_009910.2 
Cxcr4 C-X-C motif chemokine receptor 4 NM_009911.3 
Defcr1 Defensin-related cryptdin peptide-1 NM_010031.2 
F2rl1 Protease activated receptor 2 (PAR2) NM_007974.4 
GABA A Gamma-aminobutyric acid A NM_010252.4 
GABAB Gamma-aminobutyric acid B NM_019439.3 
GATA-3 GATA Binding Protein 3 NM_008091.3 
GDNF Glial Cell Derived Neurotrophic Factor NM_010275.2 
GFAP Glial Fibrillary Acidic Protein NM_001131020.1 
Gpr44 Prostaglandin D2 Receptor 2 NM_009962.2 
Hif1a Hypoxia Inducible Factor 1 Alpha Subunit NM_010431.2 
HMGB1 High Mobility Group Box 1 NM_010439.3 
I-FABP Fatty acid-binding protein 2 NM_007980.2 
Il17a Interleukin-17A NM_010552.3 
Il22ra2 Interleukin 22 Receptor Subunit Alpha 2 NM_178258.5 
Il23r Interleukin 23 receptor NM_144548.1 
Lyz1 Lysozyme 1 NM_013590.3 
Mapk1 Mitogen-Activated Protein Kinase 1 NM_011949.3 
MMP9 Matrix Metallopeptidase 9 NM_013599.2 
Muc2 Mucin 2 NM_023566.2 
Myd88 Myeloid Differentiation Primary Response 88 NM_010851.2 
Mylk3 myosin light chain kinase 3 NM_175441.5 
NFAT Nuclear factor of activated T-cells NM_010901.2 
Nfkb1 Nuclear factor NF-kappa-B p105 subunit NM_008689.2 
Nod2 Nucleotide-binding oligomerization domain-containing protein 2 NM_145857.2 
NOS Nitric Oxide Synthase 1 NM_008712.2 
NPY Neuro peptide Y NM_023456.2 
NR2B Glutamate Ionotropic Receptor NMDA Type Subunit 2B NM_008171.3 
NR2D Glutamate Ionotropic Receptor NMDA Type Subunit 2D NM_008172.2 
Ocln Occludin NM_008756.2 
P75 Nerve Growth Factor Receptor NM_033217.3 
PGP9.5 Ubiquitin C-Terminal Hydrolase L1 NM_011670.2 
Pparg PPAR-gamma, peroxisome proliferator activated receptor gamma NM_011146.1 
Rae1 Ribonucleic Acid Export 1 NM_175112.5 
Reg3g Regenerating Family Member 3 Gamma NM_011260.1 
S100BETA S100 Calcium Binding Protein B NM_009115.3 
SEMAPHORIN Semaphorin NM_011352.2 
SOX10 SRY-Box 10 NM_011437.1 
SUBP Substance P XM_006505028.1 
T-bet T-box 21 NM_019507.1 
TAAR1 Trace amine associated receptor 1 NM_053205.1 
TAAR4 Trace amine associated receptor 4 NM_001008499.1 
Tff3 Trefoil factor 3 NM_011575.2 
TGR5 G-protein coupled bile acid receptor 1 NM_174985.1 
Tjp1 Tight junction Protein 1 (ZO-1) NM_009386.1 
Tlr2 Toll-like receptor 2 NM_011905.2 
Tlr4 Toll-like receptor 4 NM_021297.2 
Tlr5 Toll-like receptor 5 NM_016928.2 
Tollip Toll Interacting Protein NM_023764.3 
trpv1 transient receptor potential cation channel, subfamily V, member 1 NM_001001445.1 
VIP Vasoactive Intestinal Peptide NM_011702.2 
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III – General Discussion 
 
 
Main findings: 
 
• High salt diet impacts gut microbiota composition and function: 
o Lactobacillus genera is reduced by HSD and this effect is reversible 
o Metabolic pathways shift, with altered metabolism of lysine, arginine, 
proline and fatty acids. 
o SCFA butyrate is reduced by HSD. 
 
• High salt diet modulates mucosal immune system in the colon and, to a 
lesser extent, in the small intestine: 
o In the colon, Rac1, IL1rap, Atf2, IL-7 and several Map kinase genes 
were upregulated whereas several chemokines and chemokine 
receptor genes were downregulated. 
o IL-6, LPS-stimulated MAPK and Acute phase response signaling 
pathways were upregulated in the colon; while leukocyte migration 
functions were downregulated. 
o In the small intestine, IL17A, Defa-rs1 and Ltb4r2 genes were 
upregulated whereas IL12a, Cxcr4 and Mef2b downregulated. 
o IL-17, TLR and p38 MAPK signaling was altered in the small intestine. 
 
• High salt diet increases RORγt+IL17+ cells in MLNs but not in intestinal lamina 
propria. 
 
• HSD exacerbated DSS and DNBS colitis in SPF mice , this effect was absent in 
germ-free mice. 
 
• Transferring gut microbiota from mice on HSD into GF mice revealed that 
maintenance of the HSD-microbiota signature is dependent on constant 
exposure to HSD. 
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 There has been extensive effort to understand the rise of chronic 
inflammatory disorders (CID), observed in the western world over the last 50 
years, and more recently in regions of the world adopting western-like 
economical and social style. Because five decades, or even a century, represent 
a very short time period for a major human population genetic shift, it has 
become clear that the increase of CID must be driven by changes in 
external/environmental factors, resulting from altered lifestyle from societies in 
developed and industrialized regions. The changes observed in dietary habits of 
the western world have been proposed as an important driver of the CID 
epidemic. Moreover, gut microbiota is seen as a key mediator between 
environmental factors such as diet, and the host health and disease.  
 
 
Diet-microbiota interaction in health and disease 
 
 Given the major impact that gut microbiota has on host health and 
disease, and the influence that diet exerts on microbiota composition and 
function, it is possible that the increased incidence of CID in the western world 
may be, at least partially, explained by changes in dietary factors that ultimately 
impact the gut microbiota. Indeed, several studies have demonstrated that the 
effect of dietary factors on gut microbiota can have profound consequences for 
the host’s health and disease (Table 1).  
 Devlin et al. observed that different Bacteroides species differ in their 
ability to produce indole, the precursor to the toxin indoxyl sulfate, and this 
capacity was dependent on the expression of tryptophanase, an enzyme that 
converts tryptophan into indole. Other Bacteroides are adapted to use fructans 
instead of tryptophan as substrate. Taking advantage of this metabolic 
difference between the Bacteroides species, the authors used a Fructo-
oligosaccharides (FOS) diet to boost the level of indole-non-producing 
Bacteroides, which outcompete indole-producing Bacteroides, with consequent 
decrease in toxic indoxyl sulfate. In a nutshell, the authors were able to shape 
General Discussion 
	 85 
microbiota composition and metabolic outcome by favouring the genetic tools 
of specific bacteria using dietary intervention[153]. 
 Furthermore, in a HSD-induced model of recurrent obesity, mice 
previously exposed to obesity cycles showed enhanced susceptibility to 
metabolic phenotype complications, and this was related to the perpetual 
microbiota dysbiosis from previous HSD cycles[204]. Two flavonoids, apigenin 
and naringenin, were shown to be persistently decreased post obese phase 
because of a combination of low dietary flavonoid availability during HFD and 
the long-standing presence of flavonoid-degrading bacteria. Transplanting 
healthy microbiota or treating mice with flavonoids ameliorated the rate of 
secondary weight regain[204]. This not only shows the long-term influence that 
dysbiotic microbiota can have on host physiology but also that it is possible to 
beneficially modulate the host physiology downstream of the microbiota by 
usage of post-biotics. 
 In our study, we showed that the effect of HSD on exacerbating colitis 
was lost in germ-free mice, demonstrating that gut microbiota is essential for 
the pathological effect of HSD. Moreover, we observed that all recipient mice in 
the microbiota transplant experiment had similar microbial profiles prior to the 
induction of DSS colitis, irrespective of the donor, and at the end of the 
experiment had the same histological and clinical level of colitis. In this 
experiment, we wanted to study whether the dysbiotic HSD-microbiota was able 
to transfer the HSD-colitis phenotype by itself. For that reason it was important 
to maintain both recipient mouse groups, control and HSD-gnotobiotic mice, on 
control diet. Unexpectedly, HSD microbiota profile converged to control one 
within 5 days thus demonstrating that the maintenance of the HSD-microbiota 
profile requires a constant exposure to HSD, and that the microbial changes 
induced by HSD are key for the determination of the colitis phenotype. 
 Moreover, we observed a decrease of the bacterial product butyrate in 
mice fed with HSD, a feature that has been linked to the development of IBD 
[184]. In a recent study, supplementing butyrate-producing bacteria to fecal 
microbiota of Crohn’s disease patients enhanced the intestinal epithelial barrier 
integrity in an in vitro system stimulating the mucus- and lumen-associated 
microbiota[205], thus supporting the role that the decrease of butyrate 
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observed in our study may have on a barrier integrity loss model in this model 
of colitis. 
 A recent study has revealed a new potential role of high salt intake, 
showing that HSD promotes neurovascular and cognitive dysfunction in mice 
through a gut-initiated Th17 response[206]. Although the role of the microbiota 
was not assessed in that study, given the effect of HSD on the microbiota, the 
microbiota-Th17 axis and the microbiota-gut-brain axis, we speculate that 
microbiota must be an important element linking HSD and cognitive 
dysfunction. Interestingly, the effect of HSD on cognitive dysfunction was 
reversible after mice returned to control diet, similar to the reversible “behavior” 
of microbiota profiles. 
 
 
 
Is high salt diet a risk factor for IBD? 
 
 Much like other CID, the incidence of IBD has been increasing, especially 
in the western regions or recently developing countries. Occurrence of IBD in 
new immigrants to countries with the high prevalence of the disease along with 
an increasing number of the disease with industrialization and westernization in 
area with previously low rate prevalence such as Iran, India, Lebanon, and South 
Korea[207], all highlight the significant effect of environmental triggers in IBD. 
The strongest environmental associations that have been identified in IBD are 
cigarette smoking and appendectomy, although neither factor alone explains 
the worldwide incidence of IBD[207]. Western diet, with high content of fat, 
sugar and salt, has been proposed to play a role in the IBD[208]. The 
consumption of salt has increased over the past decades, especially in the 
western world, reflecting the increased consumption of processed foods in a 
society with increasingly less time to dedicate to home cooking[18,19] (Fig. 1). 
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Figure 1. Self reported survey on mean sodium intake among (A) males and (B) females in the USA 
National Health and Nutrition Examination Surveys (NHANES) (Adapted from Loria CM et al, 
2001[209]). 
 
 In our study, we used two models of colitis by inducing damage in the 
epithelial barrier which leads to a pathological immune response. We observed 
that the impact of HSD on gut microbiota and immune system primes the host 
to develop an exacerbated inflammatory response following the loss of 
intestinal integrity. Although the damage to the intestinal epithelium in our 
models was acute and to some degree artificial, the impairment of intestinal 
barrier function is a hallmark of IBD. Indeed, many of the genes that are 
associated with IBD are involved in several aspects of gut barrier function, such 
as hepatocyte nuclear factor 4α (HNF4α), E-cadherin (CDH1), meprin 1A (MEP1A), 
and others[210]. Moreover, colitis has been shown to be exacerbated by HSD in 
other murine models. Tubbs et al, tested the effect of HSD in a genetically 
susceptible model that develops spontaneous colitis, the IL-10 KO, and in an 
infectious model of colitis, with Salmonella typhimurium. HSD exacerbated 
intestinal inflammation and proinflammatory cytokines in the colons of IL-10 KO 
mice. HSD also worsened the expression of proinflammatory cytokines but not 
the histological features of S. typhimurium colitis[187].  
 Until today, the role of the increased intake of sodium as a risk factor for 
the development of IBD has not been assessed clinically. Salt consumption was 
associated with hypertension and cardiovascular disease since 1960[211]. There 
is, however, very limited data on cardiovascular comorbidity in IBD. On one 
retrospective cohort, IBD patients were found to have significantly higher 
incidence of hypertension than controls[212].  
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 Taken all together, we hypothesize that HSD consumption is a risk factor 
for the development of IBD and it is a major determinant of the clinical course of 
the disease. This hypothesis is now being tested in a pan-canadian study led by 
McMaster University and supported by Canadian Institutes for Health Research, 
in which 8,000 individuals, including 4,000 patients with IBD, will be studied 
during 5 years (http://imaginespor.com). In this study, microbiota composition 
and metabolomic profiles together with detailed dietary habits will be assessed 
and linked to diseases course and severity. If the association found in our 
mouse experiments is confirmed, then a dietary intervention study will be 
initiated.  
 
 I hope this thesis has contributed to the increasing perception of the 
impact that the interaction between diet and the gut microbiota can have in the 
host’s health and disease.  
 
Future perspectives 
 
 Several open questions remain. Here is a list of future experiments and 
studies as a follow up of this thesis: 
 
• To isolate the lactobacillus bacteria and use them to supplement mice 
on HSD in order to improve the colitis severity. 
• To explore the role of butyrate and butyrate-producing bacteria on the 
HSD-exacerbated colitis model. 
• Test different genetically knock-out models that have impaired 
intestinal barrier function. 
• Using bacterial cultures to assess sensitivity of individual bacterial 
strains to high salt environment. 
• Prospective monitoring salt consumption and disease progression in 
IBD patients (currently being in process).  
• Retrospective or Case control study to evaluate the correlation 
between salt consumption and IBD prevalence/incidence. 
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The following scientific article is the result of the PhD. research work portrayed 
in this dissertation: 
 
 
Pedro M. Miranda 1,2, Giada De Palma1, Viktoria Serkis1, Jun Lu1, Marc P. Louis-
Auguste1, Justin McCarville1, Elena F. Verdu1, Stephen M. Collins1, Premysl 
Bercik1*, 2018. High salt diet exacerbates colitis in mice by decreasing 
Lactobacillus levels and butyrate production. Microbiome Journal (published) 
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